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Abstract 
Regulatory T cells (Tregs) seem to play a protective role in the pathogenesis of 
type 1 diabetes (T1D), a serious autoimmune disease. Studies using T1D murine 
models such as the non-obese diabetic (NOD) mouse have suggested that T1D 
is initiated partly due to either paucity and/or defectiveness of Tregs in the 
periphery, although other reports contradict this. In contrast Treg development in 
the thymus is thought to be normal in T1D-prone mice. However, these latter 
studies neglect to investigate different thymic Treg subpopulations such as 
precursor Tregs, newly developed Tregs and thymic resident Tregs. It is therefore 
important to establish a pattern of Treg populations for a better understanding of 
the relationship between regulatory cells and T1D.  
 
Using for the first time RAG-GFP reporter mice, this project re-investigated the 
Treg frequency and number in primary and secondary lymphoid organs in NOD 
mice in comparison to non-diabetes prone control mice. Time course flow 
cytometry studies revealed that there was a developmental fault in Treg 
generation in NOD mice; both precursor and mature Treg frequencies and 
numbers were increased with respect to control mice. However, further analysis 
of the mature Treg thymocytes demonstrated there was a paucity in newly 
developed Tregs compared to control mice, and concomitantly an increase in 
thymic resident Tregs in the NOD mice. These events were not related to intra-
thymic IL-2 levels. Interestingly, B cells may have a role in Treg development 
and/or peripheral homeostasis in an age-dependent manner.  
 
The data presented in this project provides new evidence on the inticacies of the 
relationship between Tregs and T1D, and emphasize the importance of succinct 
analyses of distinct thymic Treg subpopulations to validate this relationship.     
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Introduction 
1.1 Diabetes 
Diabetes mellitus commonly referred to as diabetes, is a metabolic disorder 
characterized by chronic hyperglycemia (increased blood sugar levels). On the 
report of Diabetes UK, only in the UK there are 4.6 million people with diabetes 
including 1 million speculated undiagnosed patients due to their unawareness of 
their condition. In addition, they state that since 1996 the number of diabetic 
people has increased more than 2-fold at an alarming rate (www.diabetes.org.uk)  
Diabetes is a result of either lack of and/or resistance to the hormone insulin. 
There are a few types of diabetes the two main types being type 1 diabetes (T1D) 
and type 2 diabetes (T2D), and others such as gestational diabetes that develops 
during pregnancy and fewer rare ones (www.diabetes.org.uk). T1D is an 
autoimmune condition in which insulin-secreting β cells are destroyed by the 
body’s own immune system resulting in diminished levels or lack of insulin 
(Devendra 2004). On the other hand, in T2D insulin resistance and insulin-
producing cell dysfunction are the major pathophysiologic factors driving this 
condition (Taylor 2013). Nonetheless, both types result in hyperglycemia 
(www.diabetes.org.uk). Insulin is a hormone produced by the pancreatic β cells 
situated in the Islets of Langerhans and is vital for normal growth and 
development by maintaining normal homeostasis of glucose, fat and protein 
metabolism (Le Roith and Zick 2001). Insulin’s main function is to inhibit 
excessive glucose being produced when blood glucose is high by impeding 
glycogenolysis (breakdown of glycogen stores), proteolysis (breakdown of 
proteins), lipolysis (breakdown of fats) and glucagon production, an ‘anti-insulin’ 
hormone (Sonksen and Sonksen 2000). Hyperglycemia is the cause of many 
complications seen in diabetic patients. As a result, monitoring and controlling 
blood glucose levels via appropriate nutrition and/or medication such as insulin 
administration, depending on the type and severity of diabetes in patients is 
crucial. Some common symptoms of diabetes are excessive urination, thirst and 
drinking alongside with short and long term effects. In the short term, excessive 
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or insufficient blood glucose can result in hyperglycemia and hypoglycemia 
respectively that leads to diabetic ketoacidoses in T1D or hyperosmolar 
hyperglycemic state in T2D patients if not treated (Daneman 2006, Longmore et 
al. 2014). In the long term, serious microvascular or macrovascular problems 
arise such as retinopathy, nephropathy, neuropathy, stroke, renovascular 
disease, limb ischaemia and enhanced risk of heart disease (Longmore et al. 
2014). Therefore, the continuation of diabetes research aiming to find a cure is of 
great importance. 
1.1.1 Type 1 Diabetes 
This project is solely concerned with T1D that accounts for 5-10% of all diabetes 
cases. Nonetheless, T1D is a serious autoimmune condition where pancreatic 
insulin-producing β cells situated in the islets of Langerhans are destroyed by the 
host’s immune system (Daneman 2006). Furthermore, T1D patients are required 
to monitor their blood glucose levels via regular finger stick blood testing followed 
by insulin injections due to insufficient or lack of insulin resulting from β cell 
destruction (Atkinson and Eisenbarth 2001, Oram et al. 2014). Ultimately, T1D 
impacts the quality of life of T1D patients and restricts their activities due to the 
short and long-term implications discussed above (Alvarado-Martel et al. 2015). 
 
1.2 The immune system 
1.2.1 Role 
The immune system is a well-balanced, complex host defence mechanism 
against a variety of pathogenic microorganisms such as fungi, bacteria, protozoa 
and viruses that threaten normal host functions. Once these pathogens invade 
the host, they are recognised by the immune system and are subsequently 
eliminated via a variety of mechanisms before they cause damage to the host. 
The immune system is sub classified into two main systems known as the innate 
immune system and the adaptive immune system. The innate immune system is 
the initial, nonspecific host response whereas the adaptive immune system is the 
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following response expressed after the innate response of the host and is highly 
specific against unique pathogen antigens. Although each system has distinct 
pathways and cells involved, effective elimination of pathogens depends on the 
synergy between the innate and adaptive immune system via cell-cell interactions 
and crosstalk as well as cytokine and chemokine secretion (Parkin and Cohen 
2001, Pancer and Cooper 2006, Chaplin 2010). 
 
1.2.2 The innate and adaptive immune system 
The innate immune system is identified as a rapid response, lacking specificity 
and is unable to form immunological memory of infection. There are several 
features composing the innate immune system’s defense mechanisms. For 
instance, physical barriers such as the tight cell-cell contacts of the epithelial cell 
layers or the overlaid secreted mucus on epithelial respiratory, gastrointestinal 
and genitourinary tracts, prevent pathogen invasion. In addition, several soluble 
proteins that are either present in biological fluids or released by activated cells 
contribute in the capture and elimination of pathogens trying to invade the host 
(Chaplin 2010). However, in the case of pathogens invading successfully the 
host, innate immune cells such as natural killer (NK) cells, mast cells, eosinophils 
and phagocytes (macrophages, monocytes, dendritic cells (DCs) and neutrophils) 
take action (Parkin and Cohen 2001). In order for these cells to be activated they 
need to be able to recognise invading pathogens. Microbial pathogens express 
unique molecular structures intracellularly or extracellularly, that allow the innate 
immune system cells to distinguish between self and nonself. These unique 
molecular structures are known as pathogen-associated molecular patterns 
(PAMPs). The cells of the innate immune system have a variety of numerous cell 
membrane receptors such as C-type lectins , scavenger receptor type A (SR-A), 
Toll-like receptors (TLRs), serum amyloid protein (SAP), mannan-binding lectin 
(MBL), C-reactive protein (CRP) etc., expressed on their cell surface, intracellular 
compartments or secreted in the bloodstream, collectively known as pattern 
recognition receptors (PRRs) that are capable of recognising PAMPs (Janeway 
and Medzhitov 2002, Iwasaki and Medzhitov 2004). Once PAMPs are recognized 
by PRRs, inflammatory and immune responses are initiated due to a cascade of 
activated signalling pathways transmitted into the cells resulting in upregulation of 
costimulatory and MHC molecules, the induction of inflammatory cytokines, 
antimicrobial genes and the adaptive immune system as well as mediating 
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phagocytosis of pathogens. Furthermore, due to lack of the innate immune 
system specificity, sometimes host tissue and cells are damaged and the immune 
system is capable of removing damaged host cells in order to prevent 
inflammation and potential responses against self-molecular structures (Parkin 
and Cohen 2001). Damage-associated molecular patterns on damaged host cells 
act as endogenous danger signals in order for the innate immune system to 
recognise them through PRRs and remove them (Shin et al. 2015). 
 
The adaptive immune system in contrast to the innate immune system, is a 
slower response with higher specificity against pathogens and is capable of 
forming immunological memory to infections (Chaplin 2010). Only higher animals 
have adaptive immunity as part of their immune system, in which immune 
responses are funnelled towards a specific pathogen (Parkin and Cohen 2001). 
The adaptive immune system is composed of T and B cell lymphocytes that have 
unique receptors against specific antigens on cells, yet each cell has its own 
specificity that might differ from another cell’s, against a certain antigen. 
Collectively among the cells, there is an enormous receptor repertoire with 
different antigen specificity expressed by T and B cells that allows them to 
recognise a vast number of antigens. This is by virtue of rearranged variable, 
diversity and joining gene segments, also known as V, D and J, respectively (see 
below) (Xu and Selsing 1994, Pancer and Cooper 2006).  In order for T and B 
cells to function they need to be activated first in order to drive targeted 
responses. Once T and B cells associate with their cognate antigen (an antigen 
specific to a certain receptor), leads to priming, activation and differentiation. The 
effector response occurs in which activated T cells migrate from the lymphoid 
tissue to the infected area and B cells differentiate into plasma cells which 
secrete antibodies (Abs) in the blood and tissue fluids homing to the infected 
area. However, despite the similar gene rearrangement process of T and B cell 
receptors, antigens are recognised differently. T cells receptors are able to bind 
to small linear peptides, whereas antibodies recognise the shape of epitopes 
(part of the antigen recognised by the immune system). Furthermore, there is a 
variety of functions of T and B cells depending on their subtype. In regards to T 
cells, T helper (Th) cells are responsible for orchestrating cells of the immune 
response as well as activating B cells whereas cytotoxic T cells are capable of 
killing directly cells that bear their cognate antigen. In regards to B cells, they 
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predominantly  produce antibodies that are the secreted form of B cell receptor 
and are able to neutralise toxins produced by invading microorganisms, enhance 
phagocytosis by labelling bacteria (opsonization), prevent adhesion of organisms 
to mucosal surfaces and collectively acting to enhance features of the innate 
immune system (Parkin and Cohen 2001).  
 
As mentioned previously, both T cell receptors (TcRs) and B cell receptors 
(BcRs) are antigen-specific resulting from a similar process of random 
rearrangement and splicing of several DNA segments encoding the antigen 
binding areas of the receptors. This results in  the production of a huge receptor 
repertoire of over 108 TcRs and 1010-1013 Ab BcRs, sufficient to respond to a 
range of pathogens encountered throughout life (Parkin and Cohen 2001, Pieper 
et al. 2013). In regards to their structure, T cells have two forms of receptors, 
each consisting heterodimeric chains. The most common one is the ɑ and β 
chain receptor and the second one is the γ and δ chain receptor. Similarly, BcRs 
have two chains known as the heavy chain and light chain. These chains are 
composed of constant and variable regions mediating effector functions and form 
antigen recognition binding sites of the antibody, respectively (Pieper et al. 2013). 
Due to the random somatic gene rearrangement and joining known as V(D)J 
recombination, results in an enormous repertoire of receptors. The heavy chain 
encodes V, D and J segments whereas the light chain encodes only V and J 
segments. In essence, individual V,D and J segments are randomly selected and 
spliced to form VDJ or VJ gene sequences that will be transcribed to produce 
different receptors contributing to clonal diversity (Fugmann 2014). This process 
is catalyzed by recombinase-activating gene enzymes (RAG) (Chaplin 2010, 
Fugmann 2014). The VDJ segments are recognised by RAG enzymes via their 
recombination signal sequences (RSS) adjacent to the each segment. Once the 
RAG enzymes bind to RSS and juxtapose them bringing the chosen gene 
segments together to be recombined, the DNA is cleaved by RAG enzymes 
exactly at the junction of the gene segment and its RSS motif, creating a DNA 
hairpin in order to join the segments. Subsequently, nucleases cleave the DNA 
hairpins at the end of the segments allowing them to join via non homologous 
end joining DNA repair factors (Schatz and Ji 2011). In addition, an enzyme 
called terminal deoxynucleotidyltransferase (TdT) is recruited and adds random 
nucleotides to the end of the DNA strands contributing to the diversity of the 
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rearranged VDJ gene (Chaplin 2010). Collectively, these processes result in the 
formation of a vast number of possible receptors. 
1.3 B cells 
B cells, so-called because discovered in Bursa of birds (Cooper 2015), major 
function is the production of antibodies although they have another physiological 
role as APCs. As previously mentioned, antibodies are able to eliminate 
pathogens via a variety of mechanisms such as opsonization enhancing 
phagocytosis as well as neutralising toxins including other mechanisms that help 
protect the host, as part of the adaptive immune response, against different 
pathogens including bacteria and viruses. In addition, B cell development initially 
occurs in the bone marrow and subsequently complete their development in the 
spleen. 
 
1.3.1 Development 
Haematopoietic stem cells (hereafter called HSCs) are situated in the bone 
marrow and are the progenitors of all major blood cell types such as erythrocytes 
(red blood cells), myeloid cells (monocyte/macrophage and granulocytes), 
megakaryocytes/platelets, natural killer (NK) cells, dendritic cells (DCs), mast 
cells and both T and B lymphocytes (Seita and Weissman 2010, Morrison and 
Scadden 2014). There are two classes of HSCs; long-term and short-term HSCs 
(hereafter called LT-HSCs and ST-HSCs, respectively). The LT-HSC subset is 
highly self-renewed throughout the host’s lifespan while the ST-HSC subset is 
able to self-renew roughly 8 weeks after differentiating from LT- HSCs (Morrison 
and Weissman 1994). The LT-HSCs are characterized by the expression of  Thy-
1.1lo, lineage (Lin)-, stem cells antigen-1 (Sca1)+, stem cell growth factor receptor 
(c-Kit)+, fetal liver kinase-2 (Flk-2)- where ST-HSCs express Thy-1lo, macrophage 
1 antigen (Mac1)lo, Lin-, Sca1+, c-Kit+ and Flk-2+ cell markers, but are both devoid 
of fms-like tyrosine kinase 3 (Flt3) expression (Weissman 2000, Christensen 
2001, Kumar et al. 2008). Collectively Lin-Sca1+c-Kit+ expressing cells are also 
known as LSK cells (Kumar et al. 2008). Henceforth, each step of differentiation 
of these multipotent cells results in a functionally irreversible maturation. Once 
LT-HSCs differentiate to ST-HSCs, they can give rise to multipotent progenitors 
20 
 
(hereafter called MPPs) that  lack the self-renewing capacity of HSCs, yet are 
able to differentiate into oligolineage progenitors giving rise to all types of blood 
cells due to MPPs’ full-lineage differentiation potential (Seita and Weissman 
2010). MPPS are also LSK cells and acquire the expression of Flt3. Throughout 
lymphoid commitment of HSCs, erythroid and megakaryocytic potential gradually 
decreases (Kumar et al. 2008). Following MPP development, the classical and 
currently prevailing haematopoietic commitment and blood lineage development, 
supports distinct myelopoiesis and lymphopoiesis originating from common 
myeloid progenitors (CMPs) and common lymphoid progenitors (CLPs), 
respectively (Adolfsson et al. 2005). CMPs have the capacity to give rise to either 
myelomonocytic progenitors (GMPs) or megakaryotic/erythroid progenitors 
(MEPs) whereas CLPs can give rise to T lymphocytes, B lymphocytes or natural 
killer (NK) cells. In addition, CLPs are distinguished based on their phenotype of 
interleukin-7 receptor (IL-7 R)+, Lin-, Thy1.1-, Sca-1lo, c-Kitlo and Flt3+ (Weissman 
2000). Through the use of Flt3 knock-out mice resulting in B and T cell 
progenitors as well as CLPs reduction in mice, the significance of Flt3 expression 
on CLPs was revealed, as Flt3 synergizes with IL-7 and stem cell factor (SCF) 
during the early stages of lymphopoiesis in order to promote lymphocyte 
proliferation (Borge et al. 1999, Adolfsson et al. 2005, Holmes et al. 2006). 
Therefore in essence, the initial lineage of multipotent cells is LT-HSCs → ST-
HSCs → MPPs → CMPs/CLPs.  Adding to the complexity of lineage 
commitment, further studies have revealed heterogeneity of the CLP population. 
For instance, MA. Inlay et al. using a new computational method of mining 
developmentally regulated genes (MiDReG), identified Ly6D expression of CLPs 
as a potential surface marker for B cell progenitors (Inlay et al. 2009). In their 
investigation they illustrated how CLPs are subdivided into two populations, the 
Ly6D- and Ly6D+ subset. Examining the potential of each subset to produce T, B 
and NK cells, revealed the ability of Ly6D- CLPs to keep their full lymphoid 
potential and give rise to all three lymphocyte types hence called all-lymphoid 
progenitors (ALPs). Whereas Ly6D+ CLPs produced mostly B cells, hence called 
B cell-biased lymphoid progenitors (BLPs) (Inlay et al. 2009). Subsequently, R. 
Mansson et al. using λ5 (a gene of B cells) reported transgenic mice crossed with 
RAG-1-GFP knock in mice in order to track λ5 and RAG-1 co-expression, 
identified three phenotypically distinct CLP subsets; λ5−Rag1low, λ5−Rag1high, and 
λ5+Rag1high cells (Mansson et al. 2010). Clonal in vitro differentiation showed that  
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λ5−Rag1low cells were capable of producing T, B and NK cells alike, λ5−Rag1high 
cells could give rise to T and B cells but not NK cells whereas λ5+Rag1high cells 
were restricted to B cell lineage generation (Mansson et al. 2010).On the other 
hand, more recently Q. Zhang et al. sought to observe three well established 
differentiation milestones in B cell commitment, Ftl3, RAG-1 and Ly6D in order to 
chart the main differentiation pathways (Zhang et al. 2013). Based on their 
findings in agreement with previous studies (Inlay et al. 2009, Tsapogas et al. 
2011), restricted B cell lineage potential was highly correlated with RAG-1 and 
Ly6D expression on CLPs. In addition, these CLP subpopulations expressed high 
levels of B cell gene transcripts such as early B cell factor 1 (Ebf1), RAG-1 and 
paired box gene 5 (Pax5), suggesting CLP commitment towards the B 
lymphocyte lineage (Zhang et al. 2013).  
 
Collectively, it seems that within the CLP stage the hierarchy is not as clear-cut 
as once thought to be and their fate depends on which lineage their 
subpopulations leans to. Therefore, combining these evidence together it is 
plausible that B cell restricted progenitor could be distinguished based on Sca-1lo, 
c-Kitlo, Flt3+, IL-7R+, Ly6D+ and RAG-1 expression together with high levels of B 
cell gene transcripts.  
 
Immediately following the CLP stage, cluster of differentiation 45R (CD45R) 
isoform B220 expression distinguishes cells restricted to B cell lineage, prior to 
CD19, a molecule expressed on all later B cell lineage stages (Hardy and 
Hayakawa 2001). In addition, evidence of a CLP subpopulation characterised as 
Lin-, B220-, CD19-, CD127+, Flt3+, Sca-1lo and c-Kitlo was able to express B cell 
lineage-associated genes, suggesting that B cell lineage commitment occurs 
prior to B220 and CD19 expression that were initially thought to be the hallmark 
of B cell lineage commitment (Mansson et al. 2008). Nonetheless, followed by the 
B cell lineage commitment and the expression of both B220 and CD19, 
development of B cells within the bone marrow progresses through a series of 
major stages known as pro B cell, pre B cell and immature B cell (Li et al. 1996). 
Each stage has its own distinct phenotypic characterisation based on B220, 
CD19, leukosialin (CD43), heat stable antigen CD24 (HSA) and immunoglobulin 
M (IgM) expression amongst others. For instance, together with B220 and CD19 
expression throughout these stages, pro B cells are characterised as 
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CD43+HSA+IgM-, pre B cells as CD43-HSA+IgM- and immature B cells as CD43-
HSA+IgM+ (Hardy et al. 1991, Li et al. 1996, Loder et al. 1999, Carsetti 2000, 
Hardy and Hayakawa 2001). Once immature B cells are formed, they migrate to 
the spleen via the bone marrow sinusoids (a type of small blood vessel) in order 
to complete their maturation process. Recent bone marrow B cell immigrants in 
the spleen are known as T1 B cells and B cells found exclusively in the primary 
follicles of the spleen are known as T2B cells (Loder et al. 1999).  
 
Collectively, studies have shown that B cell development processes seem to be 
governed by the expression of certain genes and transcription factors in addition 
to the presence of cytokines contributing to their developmental process (Li et al. 
1996, Hardy and Hayakawa 2001, Tokoyoda et al. 2004). Throughout the bone 
marrow, a small amount of stromal cells express CXC chemokine ligand 12 
(CXCL12) that is vital during B cell development as it maintains them spatially 
within certain niches in the bone marrow during their development progression 
(Tokoyoda et al. 2004). In regards to gene expression, inactivation of the E2A 
gene that is vital in Ig gene rearrangement during the pro and pre B cell stage, 
was demonstrated to halt the early B cell developmental stages where B220 
expression was being upregulated (Zhuang et al. 1996, Bain et al. 1997). On the 
other hand, although mice lacking EBF had more B lineage cells at the B220 
stage, they failed to progress to subsequent stages possible due to the failure of 
Ig rearrangement (Lin and Grosschedl 1995). Another important transcription 
factor for the generation of both myeloid and lymphoid lineages is PU.1 that 
regulates the differentiation and the cytokine-dependent proliferation of precursor 
cells (DeKoter et al. 1998). In addition, differing concentrations of PU.1, low or 
high, determine whether the cells will develop into either B cell or macrophage, 
respectively (DeKoter and Singh 2000). Low levels of PU.1 allow lymphoid 
commitment due to upregulation of IL-7Rɑ, EBF and Pax5 transcription factor 
expression, which are vital in the process of B cell lineage commitment and 
ultimately their development (DeKoter et al. 2002, Hagman and Lukin 2006). In 
contrast to PU.1 which acts prior to CLPs on progenitors enhancing CLP 
differentiation, E2A, EBF1 and Pax5 factors act downstream the CLP stage in 
order to promote B cell lineage progression. E2A transcription factor was 
implicated in early B cell lineage development due to the activity of its binding 
function once B lymphopoiesis is initiated. In addition, E2A consists of two basic-
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helix-loop-helix (HLH) proteins known as E12 and E46 that have been shown to 
be equally important in B cell development as demonstrated using mice lacking 
either E12 or E47 (Bain et al. 1997, Hagman and Lukin 2006). At the beginning of 
B lymphopoiesis, alongside with E2A activity is EBF1, and both of them 
coordinately activate the expression of B cell genes crucial for Ig heavy chain 
gene rearrangements (Busslinger 2004). In addition, factor forkhead box protein 
1 (Foxo1) seems to be part of the transcription factors promoting commitment to 
B cell lineage, by activating the expression of RAG-1 and RAG-2 (Amin and 
Schlissel 2008, Lin et al. 2010). Furthermore, EBF1 initiates the expression of 
Pax5 transcription factor that is also important in B cell lineage restriction while 
being regulated by PU.1 (Lin et al. 2010). In essence, Pax5 represses the 
expression of non-B cell lineage genes such as Notch1, myeloperoxidase (MPO) 
and M-CSFR, while activating B cell lineage specific genes such as BLNK, Igɑ 
and CD19 (Busslinger 2004). In addition, using a retroviral vector in order to force 
Pax5 expression in HSCs resulted in blockade of T cell lineage development but 
not NK development, in favor to B cell lineage fate (Cotta 2003). Later on, mice 
lacking Pax5 in mature B cells due to conditional deletion resulted in the 
formation of functional T cells with Ig heavy and light chain rearrangements 
suggesting dedifferentiation of mature peripheral B cells into multipotent 
progenitors (Cobaleda et al. 2007). Therefore Pax5 seems to be a crucial 
transcription factor more for the progression rather than commitment that was 
believed previously, of B cell lineage (Welinder et al. 2011). Nonetheless, 
transcription factors and activation of B cell lineage specific genes, allow the 
progression of B cell progenitors to subsequent developmental stages.  
 
1.3.2 B cell receptor  
BcR rearrangement of the IgM heavy chain is an essential step initiated at the pro 
B cell stage in order to progress to the pre B cell stage (Raff et al. 1976, 
Grawunder et al. 1995). Followed by IgM heavy chain rearrangement, a 
surrogate light chain (composed of the λ5 and VpreB proteins) that is structurally 
similar to a light chain, is coupled with the heavy chain to form a pre-BCR. Prior 
to the light chain rearrangement of pre-B cells, surrogate light chain genes are 
silenced which terminates the expression of pre-BcR (Burrows et al. 2002). As 
mentioned previously, pathogen recognition by B cells is possible due to their 
highly specific receptor and numerous complex mechanisms also result in highly 
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diverse BcR repertoire capable of recognizing a vast amount of pathogens (Xu 
and Selsing 1994, Pancer and Cooper 2006). The BcR is a transmembrane 
protein and similarly to an antibody’s structure, it is composed of two parts, two 
heavy chains and two light chains. Both the heavy and light chains consist of 
constant and variable regions in which the variable regions of the chains are 
positioned next to each other. The variable regions of the chains combined form 
the antigen binding site. Once an antigen binds on the BcR, a cascade of 
signalling pathways results in the differentiation of B cells into plasma cells. 
Subsequently, antibodies are secreted by plasma cells into the bloodstream in 
order to eliminate pathogens (Parkin and Cohen 2001, Pieper et al. 2013). There 
is a variety of antibody isotypes such as IgA, IgD, IgE, IgG and IgM due to 
different types of heavy chains: ɑ, δ, ε, γ, μ, respectively (Janeway 2005). The 
function and niche of each antibody isotype differs among them. For instance IgA 
is vital for mucosal immunity (Underdown and Schiff 1986) and IgE is involved in 
allergic responses (Pier et al. 2004). Nonetheless, V (D) J recombination in order 
to form a vastly diverse receptor repertoire results in the formation of autoreactive 
B cells as well, targeting self-antigens (Goodnow 1992). Therefore, self-tolerance 
mechanisms evolved in order to bypass the actions of these self-reactive cells 
and ultimately prevent autoimmune diseases. These censoring mechanisms 
include clonal deletion, receptor editing, receptor dilution and clonal anergy 
(Hartley et al. 1993, Cornall et al. 1995, Goodnow et al. 2009, Manjarrez-Orduño 
et al. 2009). Regarding B cell clonal deletion, when the IgM of immature B cells 
situated in the bone marrow binds and responds to self-antigens, results in 
downregulation of IgM expression and maturation arrest leading to premature 
autoreactive B cell elimination (Hartley et al. 1993, Cornall et al. 1995). However, 
autoreactive B cells get another chance to escape elimination by rearranging 
their autoreactive light chain to a non-autoreactive one (Cornall et al. 1995). 
Clonal anergy of autoreactive B cells in essence implies the inability of B cells to 
respond to their antigen due to chronic stimulation making them functionally 
inactive (Cornall et al. 1995, Hardy and Hayakawa 2001, Manjarrez-Orduño et al. 
2009). In addition, higher affinity interactions to self-antigens by IgM seem to 
result in deletion and lower-affinity interactions result in either receptor editing or 
clonal anergy (Hardy and Hayakawa 2001). Receptor editing of autoreactive B 
cells can only occur within the bone marrow whereas the rest of self-tolerance 
mechanisms can occur in the periphery as well (Cambier et al. 2007). 
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1.4 T cells 
1.4.1 Development 
The majority of hematopoietic lineages develop in the bone marrow however, T 
cells complete their development in the thymus, hence called T cells. There is a 
constant input of T cell progenitors migrating from the bone marrow via the 
bloodstream to the thymus. This is necessary as thymocytes are not self-
renewing in contrast to the bone marrow hematopoietic stem cells (Heinzel et al. 
2007). However, the exact identity of the cell type that migrates from the bone 
marrow, settles in the thymus and acts as a progenitor of T cells is still 
undisclosed (Zlotoff and Bhandoola 2011).  
 
As mentioned in Section 1.3, all blood cells including lymphocytes originate from 
the LSK (Lin- Sca+ c-Kit+) HSCs situated in the bone marrow (Kumar et al. 2008). 
Subsequently, LSK HSCs differentiate into the non self-renewing MPPs that can 
give rise to all types of blood cells (Seita and Weissman 2010). Thereafter MPP 
differentiation, a more recent alternative and more complex model of HSC 
lineage commitment, supports the formation of lymphoid-primed multipotent 
progenitors (LMPPs) prior to CLP generation (Adolfsson et al. 2005, Drissen et 
al. 2016). LMPPs are phenotypically characterised as Lin- Sca+ c-Kit+ Flt3+ 
whereas CLPs are characterised as Lin- Thy1.1- Sca-1lo c-Kitlo Flt3+ and IL-7Rɑ+ 
(Weissman 2000). LMPPs can give rise to lymphocytes, NK cells, macrophages 
and granulocytes whereas CLPs are capable of only producing T cells, B cells 
and NK cells (Weissman 2000, Adolfsson et al. 2005, Drissen et al. 2016).  
 
In an effort to search for thymic settling progenitors (TSPs), Flt3 was found to be 
expressed in all TSPs in addition to chemokine receptor (CCR) 7 and chemokine 
receptor 9 that seem to be important for efficient thymic settling (Adolfsson et al. 
2005, Zlotoff et al. 2010). Both chemokine receptors are required for an effective 
thymic settling as using CCR7 and CCR9 double knockout mice resulted in 
severely reduced levels of thymic settling (Zlotoff et al. 2010). Therefore, CCR7 
and CCR9 expressing LMPPs or MPPs, could be potential TSPs. After thymic 
entry by TSPs, development of early thymic progenitors (ETPs) is followed by a 
well-defined intrathymic T cell development hierarchy known as the double 
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negative (DN) phase that is subdivided in four stages (DN1-4) where neither CD4 
nor CD8 molecule is expressed. Henceforth, the spatial location of T cells 
through distinct thymic microenvironments is crucial for the perception of 
differentiating signals and ultimately their successful development progression. 
TcR rearrangement initiates during the DN phase and in particular in DN3, by the 
mechanisms described previously (see section 1.2) (Starr et al. 2003). Ensuing 
TcR rearrangement and other T cell developmental checkpoints, leads to the co-
expression of CD4 and CD8 molecules, a phase known as double positive (DP). 
During the DP phase, T cells are subjected to another developmental checkpoint 
known as positive selection in which thymic cortical epithelial cells (cTECs) 
expressing major histocompatibility complex (MHC) class I and II, play a major 
role in T cell fate. At this point, TcRs that are able to recognise either MHC-class I 
or MHC-class II at a moderate affinity, will receive survival and maturation signals 
allowing them to progress with their development. Depending on the strength of 
interaction between MHC-class and TcR was able to associate with, will also 
direct the type of T cells they become such as CD4+ or CD8+. For instance during 
positive selection, TcR that associates MHC-class I or MHC-class II will develop 
into CD8 (CD8+) or CD4 (CD4+) single positive (SP) T cells, respectively. 
However, TcRs that are unable to recognise either MHC-class or bind too avidly, 
fail to receive survival signals or receive a death signal, respectively and die by 
apoptosis (Starr et al. 2003, Zlotoff et al. 2010). Collectively, positive selection 
allows immature DP T cells that express TcRs with intermediate affinity towards 
MHC complexes to differentiate into mature SP thymocytes (Starr et al. 2003, 
Klein et al. 2014). Succeeding positive selection, T cells migrate from the thymic 
cortex to the thymic medulla where negative selection of SP T cells is initiated by 
dendritic cells and thymic medullary epithelial cells (mTECs) (Brocker 1997). 
Autoimmune regulator (AIRE) gene is critical in negative selection as it is capable 
of expressing tissue specific self-antigens (TSAs) that are displayed by mTECs 
(Anderson and Su 2011). mTECs can then present TSAs alongside MHC 
molecules to T cells in order to check if they would react against the host’s 
antigens and depending on the affinity between the TcR and the TSA will 
determine their fate in development (Nossal 1994, Anderson and Su 2011). 
Developing T cells that react to TSA-MHC complex with high affinity are then 
eliminated by receiving death signals in order to prevent their maturation and 
migration in the periphery. In the case of these self-reactive T cells escaping to 
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the periphery, could result in damage of the host’s self-tissue as they cannot 
distinguish between self and nonself antigens. This aberrant response is known 
as autoimmunity (Nossal 1994, Starr et al. 2003). Collectively, although negative 
selection is crucial for the release of non autoreactive T cells in the periphery, it 
also contributes as a first line of defence preventing autoimmunity via T cell 
tolerance (see section 1.3) (Walker and Abbas 2002).  
 
Similarly to B cell development (section 1.3), expression of certain genes and 
transcription factors, is critical for T cell development as they navigate from 
progenitors into lineage commitment and progression in subsequent 
development. As previously mentioned, followed by TSPs entering the thymus, 
comes the development of ETPs. However, in order for TSPs to progress into the 
ETP stage, a number of vital interconnected transcription factors are required 
such as T cell factor (TCF-1), GATA-binding protein 3 (Gata3) and Notch 
homolog 1 (Notch1) including many others. Deficiencies in any of these 
transcription factors have no effect on ETP progenitors such as bone marrow and 
blood LSK progenitors however, results in a decrease of the ETP population 
(Busslinger 2004, Sambandam et al. 2005, Hosoya et al. 2009, Zlotoff et al. 
2010, Weber et al. 2011). For instance, Notch signalling is crucial for imposing T 
cell identity and maturation initiating from the bone marrow continuing to the 
thymus, as events involved in thymic precursors progression, are driven by this 
pathway and prevents apoptosis of developing T cells (Deftos et al. 1998, 
Busslinger 2004, Yui and Rothenberg 2014). In addition, it seems that some of 
the T cell progenitors at early stages of the DN phase, may still exhibit B cell 
lineage capacity (Porritt et al. 2004). However, T cell development is promoted 
due to the expression of Notch1 in the bone marrow as it was observed to 
suppress B cell lineage commitment by suppressing transcription factors that are 
essential in B cell development, such as Pax5. Furthermore, constitutive 
expression of Notch1 results in a halt of B cell lymphopoiesis and ectopic T cell 
development of immature CD4+CD8+ T cells in the bone marrow whereas 
inactivation of Notch1 results in deficient T cell fate and development as well as 
ectopic development of B cells in the thymus (Radtke et al. 1999, Pui et al. 1999, 
Han et al. 2002). Collectively, these observations illustrated the critical role of 
Notch1 expression for T cell development in addition to the importance of a 
balanced Notch1 expression for normal lymphocyte development. Additionally, 
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Notch signals upregulate the expression of TCF-1 that is also vital in T cell 
commitment by assisting in the expression of T-lineage genes, including GATA3 
and Bcl11b transcription factors. GATA3 is required for the generation of ETPs 
and subsequently control directly or indirectly the development of T cells (Ting et 
al. 1996, Hosoya et al. 2009). In addition, Bcl11b deletion was shown to result in 
either diversion to NK cell lineage development or halt of T cell development, 
illustrating Bcl11b’s crucial role in maintaining T cell lineage commitment (Weber 
et al. 2011). Furthermore, as previously discussed, E12/E46-composed E2A 
protein is not only important in B cell lymphopoiesis (see section 1.3), but also in 
T cell lymphopoiesis and development as well (Dias et al. 2008). E2A protein was 
illustrated to be needed for proper LMPP development as well as assisting the 
transition from the DN phase to the DP phase (Bain et al. 1997, Dias et al. 2008). 
Another essential transcription factor for T cell development and differentiation, is 
the runt-related transcription factor known as RUNX. RUNX was illustrated to 
contribute in the initial progenitors response towards T cell lineage commitment 
as well as transition from DN2 to DN3 phase (Rothenberg et al. 2008). Moreover, 
the synergy between RUNX, GATA3 and Th-POK (T-helper-inducing 
POZ/Kruppel-like factor) is vital for T cell development as they assist in 
determining the CD4/CD8 lineage commitment (Collins et al. 2009). Altogether, T 
cell development depends on a vast number of transcription factors working 
together in order to allow complex T cell specific development processes to take 
place. 
 
1.4.2 T cell receptor development 
The production of self-tolerant yet versatile TcRs relies on accurate coordination 
of the antigen-receptor recombination process, differentiation as well as selection 
processes taking place during development in the thymus. As previously 
mentioned, TcR development initiates at the early stages of T cell development 
during the DN phase (Ebert et al. 2010). The TcR is composed of two disulphide-
linked heterodimeric membrane proteins, TCRɑ and TCRβ chains or TCRγ and 
TCRδ chains (Nemazee 2006). T cells expressing TCRɑ and TCRβ are referred 
to as ɑβ T cells and T cells expressing TCRγ and TCRδ are referred to as γδ T 
cells with ɑβ T cells being the most common ones found in circulation (Pieper et 
al. 2013). Furthermore, TcR construction is crucial for T cell development as it 
allows T cells to progress through development checkpoints in the thymus. For 
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instance, following TCRβ rearrangement, during the DN phase thymocytes with a 
functional TCRβ chain can then express a pre-TCR that is a complex composed 
of CD3 molecules, a pre-TCRɑ chain that is invariant and an incipient TCRβ 
chain that is critical for early T cell development (Yamasaki and Saito 2007). 
Subsequently to the generation of pre-TCR, DN cells are then allowed to 
transition from the DN phase to the DP phase and this process is known as β-
selection. Using pre-TCRα or TCRβ KO mice, suggested a key role of pre-TcR as 
a molecular sensor for subsequent T cell development by triggering survival, 
proliferation and expression of either CD4 or CD8 as well as TCRɑ 
rearrangement (Mombaerts et al. 1992, Yamasaki and Saito 2007). After β-
selection, during the DP phase TCRɑ rearrangement occurs that results in the 
generation of a mature ɑβTcR (Jones and Zhuang 2007). DP cells will then 
undergo positive selection as mentioned previously that will filter out DP cells with 
non functional TcRs and enable DP cells with functional TcRs to become either 
CD4+ or CD8+ SP cells. Finally, T cells expressing a functional TcR will undergo 
negative selection in order to eliminate autoreactive cells prior to migration in the 
periphery (Starr et al. 2003, Jones and Zhuang 2007).  
 
1.4.3 Subsets of T cells 
Following T cell commitment into either CD4+ or CD8+ T cells, depending on the 
expression of either CD4 or CD8 glycoprotein surface molecule, respectively, 
comes the sub-classification of T cells into different types such as Th cells, 
cytotoxic T cells, regulatory T cells (Tregs) and memory T cells, each exhibiting 
different functions (Golubovskaya and Wu 2016). For instance, Th cells can 
differentiate further into different subsets such as Th1, Th2, Th3, Th9, Th17, 
Th22, follicular helper T cells (Tfh) as well as Tregs. Each subset can be 
distinguished based on their cytokine profile and have a different effect on the 
adaptive immune response. Th cells are vital to the immune system especially 
adaptive immunity as they assist in B cell activation and ultimately antibody 
secretion, as well as in elimination of targeted infected cells by assisting in the 
activation of cytotoxic T cells. Therefore, in essence Th cells assist other immune 
cells to do their function via cytokine secretion. However, prior to this, Th cells 
need to be activated by APCs displaying peptide antigens by their MHC-class II 
surface molecules for Th cells to respond to via their TcR and CD4 surface 
molecule acting as a coreceptor to stabilize this interaction by binding to MHC-
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class II (Alberts et al. 2002, Golubovskaya and Wu 2016). In regards to cytotoxic 
T cells (CTLs), characterised by the expression of CD8, monitor all the body’s 
cells and can either directly or indirectly destroy infected cells i.e. by a virus, by 
recognising antigens presented by MHC-class I molecules, in order to prevent 
viral spread to other cells and protect the host’s integrity. There are three distinct 
pathways CTLs can eliminate targeted cells, one involving cytokine secretion 
such as interferon γ (IFN-γ) and tumour necrosis factor ɑ (TNF-ɑ), and the other 
two involve direct cell-cell contact between CTLs and target cells which ultimately 
result in apoptosis of targeted cells. However, sometimes CTLs can inflict cellular 
damage towards a host’s organ due to the recognition of a self-antigen unique to 
that organ as non-self that initiates an immune response against it. This can 
ultimately result in an autoimmune disease, such as T1D (see section 1.7) 
(Andersen et al. 2006). Another subtype of T cells are Tregs. Tregs are vital in 
balancing immune responses of the immune system so that there is minimal self-
tissue damage. In addition, Tregs are required for maintaining peripheral 
tolerance and ultimately preventing autoimmune diseases such as T1D and limit 
chronic inflammatory diseases (see section 1.7) (Vignali et al. 2008). 
Suppression of harmful immune responses are speculated to occur either via the 
production of inhibitory cytokines such as IL-10 and transforming growth factor β 
(TGF-β) (Walker and Abbas 2002) or cytotoxic T lymphocyte associated protein 4 
(CTLA-4) (McCoy and Le Gros 1999). Tregs are thought to also suppress effector 
T cells (Th and CTLs alike) by inducing cell death either via cytokine deprivation 
by ‘consuming’ local IL-2 that is vital for other T cells survival  or cytolysis (Vignali 
et al. 2008, Shalev et al. 2011). Additionally, Tregs are thought to regulate either 
the maturation and/or function of DCs that are required for effector T cells 
activation (Vignali et al. 2008). However, there are many biological questions 
regarding Treg function and even their development that will be discussed in 
more detail later on. 
 
1.4.4 Activation of T cells 
Antigen presentation is a crucial process by which cells of the innate immune 
system communicate with the adaptive immune system. This way the adaptive 
immune system is alerted and able to mount an appropriate response against 
invading pathogens. Professional APCs such as DCs and additional cell lines 
with antigen-presenting capabilities such as B cells and macrophages, search for 
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invading pathogens that once encountered and recognised via APCs’ PRRs (see 
section 1.2), are then internalised (Kapsenberg 2003, Mogensen 2009). 
Subsequently, pathogens are broken down internally by APCs and the pathogen-
associated antigens are displayed by either MHC-class I or II that will activate 
CD8+ or CD4+ T cells, respectively (Underhill et al. 1999, Kapsenberg 2003). In 
addition to T cells recognising their cognate antigen displayed by the 
peptide/MHC complex situated on APCs, there are two more signals required in 
order for T cells to become activated. Therefore, three distinct signals are needed 
in total for the activation of naive T cells (Corthay 2006). Signal one involves the 
antigen-specific recognition of peptides by TcRs, that are presented by MHCs on 
APCs. Signal two, is provided by the binding of co-stimulatory molecules CD80 
and CD86 found on APCs, and CD28 molecule found on T cells. In addition, 
costimulatory molecules of APCs are only expressed when activated during an 
inflammatory response which ensures T cell activation only when necessary. 
Lastly, signal three relies on released cytokines by APCs that bind on their 
cognate receptor on T cells and direct T cell differentiation in different subtypes. 
For instance, T cell differentiation into various effector phenotypes such as Th1 or 
Th2 including others, is determined by the signals provided by APCs and the 
most appropriate immune response required that is dictated by the innate 
immune response via APCs (Scott 1993, Corthay 2006). However, in contrast to 
CD4+ T cells that recognise and respond to MHC-class II, CD8+ T cells will 
respond to MHC-class I in a process known as cross-presentation in which for 
instance, exogenous antigen taken up by an APC is then cross-presented on 
MHC-class I to activate CD8+ T cells (Rock and Shen 2005). Generally, 
endocytosed or phagocytosed antigens originating from outside the cell also 
known as exogenous antigens, are processed and subsequently displayed by 
MHC-class II, whereas processed antigens originating from within virus-infected 
or abnormal/cancerous cells also known as endogenous antigens, are expressed 
on MHC-class I (Wieczorek et al. 2017). Additionally, MHC-class I complexes are 
presented on all nucleated cells which allows them to alert activated CD8+ 
cytotoxic T cells in the case of viral infection or transformed in an offending state 
such as cancer (Rock and Shen 2005). Therefore, following recognition of MHC-
class I by CD8+ T cells in combination with binding to costimulatory molecules 
mentioned previously present on APCs, naive CD8+ T cells are activated and 
differentiate into effector CTLs (Kaech and Ahmed 2001). CTLs are then capable 
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of eliminating target cells expressing their cognate antigen displayed on MHC-
class I complex via highly specific mechanisms such as TNF-ɑ and IFN-γ 
cytokine secretion that ultimately result in target cell apoptosis, cytolytic activity 
leading to cell death either by caspase cascade or CTL release of cytotoxic 
perforins and granzymes (Andersen et al. 2006).  
 
1.4.5 T cell tolerance 
As in BcR diversity of B lymphocytes (see section 1.3), similarly T cells possess 
highly diverse TcRs due to somatic gene rearrangement that can also potentially 
result  in the formation of autoreactive TcR clones against host self-antigens. 
Therefore, in order to avert the generation, spread and action of these unwanted 
autoreactive T cells, a variety of self-tolerance mechanisms evolved (Abbas et al. 
2004). As mentioned previously, negative selection is a crucial educational step 
for thymocytes in order to prevent autoreactive T cells escaping to the periphery. 
However, this process is not 100% effective due to different factors such as the 
inability to express all self-antigens in the thymus, therefore lacking T cell 
tolerance towards those missing self-antigens. In addition, negative selection is 
not as stringent in deleting all developing thymocytes with autoreactive receptors, 
therefore some thymocytes with a degree of autoreactivity escape to the 
periphery and are left to be dealt with by other backup self-tolerance 
mechanisms. If negative selection was stricter with a lower binding affinity 
threshold between TcR and MHC/peptide complexes, would result in a narrower 
repertoire and ultimately reduce their ability to fight against pathogens. Therefore, 
peripheral tolerance mechanisms evolved in order to maintain self-reactive cells 
that have escaped central deletion (Walker and Abbas 2002). Such mechanisms 
include deletion by apoptosis, induction of functional anergy leading to 
unresponsiveness towards antigens or suppressive action by Tregs (Abbas et al. 
2004). Failure of self-tolerance mechanisms would potentially result in the 
accumulation of uncontrolled autoreactive lymphocytes, therefore is thought to be 
correlated with autoimmune diseases.  
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1.5 Regulatory T cells 
The existence of a T cell subpopulation (now known as Tregs) with 
immunosuppressive abilities, was uncovered by the seminal observation in 1969 
by Y. Nishizuka and T. Sakakura. A severe organ-specific autoimmune disease 
was documented followed by neonatal thymectomy (removal of the thymus), yet 
was prevented by CD4+ T cell transfer from wild type healthy mice (Nishizuka 
and Sakakura 1969). This documentation elucidated the thymic origin of Tregs 
capable of preventing autoimmunity by suppressing immune responses.  
 
1.5.1 Development 
Up until the TcR gene rearrangement phase, T cells and Tregs seem to exhibit 
the same developmental pathways (See section 1.4). During TcR gene 
rearrangement of developing T cells results in the generation of TcRs capable of 
recognising self-antigens at different intensities and timescales. T cells that 
recognise self-antigens with either really high affinity or really low affinity are 
eliminated via apoptosis or death by neglect, respectively. However, the most 
recognised model in regards to Treg development suggests that Tregs originate 
from developing T cells stimulated via their TcR at relatively high affinity against 
self-antigens, yet below the threshold needed to promote apoptosis (Ohkura et al. 
2013). This stimulation seems to activate the expression of the forkhead box P3 
(Foxp3) transcription factor by CD4+ SP T cells, that is essential in Treg 
development and function (Hori 2003, Fontenot et al. 2003, Ohkura et al. 2013). 
On the other hand, others have suggested an alternative model in which Treg 
development is significantly determined by unknown trans-acting factors acting 
on DN cells prior to the expression of TcR (Pennington et al. 2006). Nonetheless, 
the mechanisms how TcRs are then biased towards Treg lineage is unclear 
therefore the previous model is more accepted due to more supporting evidence. 
In an effort to elucidate Treg development, investigations have identified CD4+ 
CD25hi Foxp3-  T cells as Treg precursors as this subset was observed to be 
highly enriched with cells that would subsequently express Foxp3 and following 
TcR selection would be termed as mature Foxp3+ Tregs (Fontenot et al. 2005, 
Maynard et al. 2007, Lio and Hsieh 2008).  
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Although engagement with the TcR is essential for thymic Treg development, it is 
not sufficient and therefore additional signalling pathways are needed. An 
example is the epigenome that seems to play a key role in Treg development. 
For instance, TcR stimulation at a certain period of time assembles a Treg-cell-
type DNA hypomethylation pattern resulting in accessibility and enhancing 
transcription of certain genes associated with Treg-specific molecules or Treg 
function such as Foxp3, Eos and CTLA-4 (Ohkura et al. 2012). Therefore, 
collectively with the epigenomic events and Foxp3 expression, developing T cells 
are driven towards a stable Treg lineage. Interestingly, Foxp3 expressing T cells 
without the Treg-specific epigenome results in the generation of unstable Tregs 
whereas T cells with Treg-specific epigenome yet lacking initial Foxp3 
expression, can still express Foxp3 and differentiate into functional Tregs 
(Ohkura et al. 2013). Furthermore, cytokines such as IL-2, IL-7 and IL-15 seem to 
play a key role in thymic Treg development since mice with either deficient IL-2, 
IL-7 or IL-15 receptors, demonstrated a significant decrease in thymic Treg 
numbers (Bayer et al. 2007, Vang et al. 2008, Apert et al. 2017). IL-2 is the most 
vital cytokine for Treg development as Tregs classically express CD25 which is 
the high affinity subunit of the IL-2 receptor for IL-2 and is required for Foxp3 
expression allowing generation of functional Tregs (Stephens and Mason 2000, 
Burchill et al. 2007). Additionally, there are signalling pathways downstream of 
the TcR and cytokine receptors involved in Treg development such as IL-2, that 
have also been suggested to have a role in Treg development such as nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) and Janus 
Kinase/Signal Transducer and Activator of Transcription (JAK-STAT) pathways, 
respectively (Hayden and Ghosh 2011, Gilmore et al. 2016; Mahmud et al. 2013). 
For instance, the NF-κB family of transcription factors are a key regulator of 
genes expressed that are essential for the development and function of the 
immune system (Gilmore et al. 2016). TcR signalling can activate various 
pathways and one of them is the NF-κB signalling pathway that has been 
suggested to be involved in Treg development (Feuerer et al. 2009). NF-κB 
seems to be the pioneer transcription factor of Foxp3 expression as it enhances 
the accessibility of the Foxp3 locus to the general transcription machinery (Long 
et al. 2009). As a result differentiation of thymocytes into Foxp3 expressing Tregs 
depends on NF-κB signalling pathway. In regards to signalling pathways 
downstream of cytokine receptors involved in Treg development, the JAK-STAT 
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pathway seems to be important. The JAK-STAT pathway is one of the many 
pleiotropic signalling cascades essential for development and homeostasis in 
animals (Eyles and Hilton 2003). Regarding Treg development, IL-2 signalling 
activates JAKs which then phosphorylate STATs in particular STAT5a/b. Using 
STAT5a/b knockout mice and tissue-specific Stat5 deletion, STAT5a/b was 
illustrated to be important for both the development and maintenance of Tregs as 
well as Foxp3 expression (Yao et al. 2007). In addition, STAT3 was found to 
regulate Foxp3 by attenuating its expression via the mediation of IL-6 signals 
(Kasprzycka et al. 2006). Alongside these signalling pathways, CD28-
CD80/CD86 and CD40-CD154 pathways seemed to play a role in Treg 
development (Salomon et al. 2000, Tai et al. 2005, Spence and Green 2008). 
Deletion of genes encoding CD28 or its ligands CD80 resulted in significant 
reductions of thymic and peripheral Tregs elucidating their importance in Treg 
development (Salomon et al. 2000, Tang et al. 2003). Furthermore, CD28 signals 
were linked with earlier stages of Treg development at the CD25+Foxp3- 
precursor stage prior to TcR signalling and is also suggested to protect 
developing Tregs from negative selection (Lio et al. 2010, Klein and Jovanovic 
2011). On the other hand, although deficiency in CD40 or CD154 resulted in 
roughly 50% reduction of thymic and peripheral Tregs (Guiducci et al. 2005), 
CD40-CD154 signalling pathway did not seem to be required for precursor Treg 
development, but instead having an effect on later stages in Treg development 
(Cuss and Green 2012). Nonetheless, the documented peripheral Treg reduction 
is not clear whether it is due to decrease in thymic output or decrease in 
peripheral Treg homeostasis (Guiducci et al. 2005, Spence and Green 2008). 
Ultimately, once Tregs are mature and functional they can either migrate from the 
thymus to the periphery in order to maintain immune responses or may be 
retained in the thymus (Cuss and Green 2012). 
 
As mentioned previously briefly, additionally to the development of naturally 
derived thymic Tregs (nTregs or tTregs) described above, Tregs can also be 
induced in the periphery from naive conventional T cells and are known as iTregs 
or adaptive Tregs (Bluestone and Abbas 2003, Klein and Jovanovic 2011) 
(Ohkura et al. 2013). TGF-β was found to be involved in many aspects of T cells 
such as their development, homeostasis and function (Gorelik and Flavell 2000, 
Li and Flavell 2008). In addition, several studies have illustrated the importance 
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of TGF-β molecule in causing Foxp3 upregulation in peripheral naive T cells 
resulting in the generation of functional iTregs (Chen and Konkel 2015). T cell-
specific deletion of TGF-β suggested that TGF-β was critical for the homeostasis 
and maintenance of Foxp3 of peripheral Tregs as there were no detrimental 
effects upon thymic Treg development (Li et al. 2006, Marie et al. 2006). In 
regards to the mechanisms underlying the activation of Foxp3 by TGF-β, seems 
to involve Smad3 and NFAT transcription factors downstream TGF-β and the 
TcR, respectively, are thought to co-operatively bind directly to conserved non 
coding sequence 1 (CNS1) that is an enhancer element in the Foxp3 gene, and 
activate it (Tone et al. 2008). However, TGF-β is also involved in the 
differentiation of naive T cells into Th17 cells (Mangan et al. 2006), suggesting 
the involvement of other signals such as retinoic acid that inhibits Th17 
development (Xiao et al. 2008). Collectively, peripheral Tregs are comprised of 
two distinct developmental origins, mature nTregs that developed in the thymus 
and subsequently migrated in the periphery, or iTregs generated from peripheral 
naive CD4+ T cells. Nonetheless, identifying markers to distinguish among 
nTregs and iTregs was challenging as they are both phenotypically very similar 
(Lin et al. 2013). Although both nTreg and iTregs express CD25, Foxp3, GITR 
and CTLA-4, nTregs seem to have higher expression of neuropilin 1 (Nrp1), 
Helios (Ikzf2), programmed cell death-1(PD-1) and CD73 in comparison to iTregs 
with only Helios and Nrp1 being able to individually provide distinction between 
nTregs and iTregs (Yadav et al. 2012, Lin et al. 2013).  
 
1.5.2 Role and function 
As previously mentioned, CD4+ Tregs are mostly involved in the control of 
autoreactive T cells, thus maintaining immunologic self-tolerance (Sakaguchi 
2004). Other suggested functions of Tregs include modulating the magnitude of 
immune responses, oral tolerance, feto-maternal tolerance as well as 
suppression of allergy, asthma and pathogen-induced immunopathology (Corthay 
2009). Tregs can affect proliferation, differentiation and effector function of 
multiple immune cell types (DiPaolo et al. 2005, Sojka et al. 2008). Several 
mechanisms have been proposed for Treg function yet there is still a debate 
whether Tregs inhibitory activity depends on direct cell-cell contact. One of the 
suggested Treg mechanisms suppressing effector T cells is depriving them from 
IL-2 that is vital for their survival and proliferation and ultimately results in 
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apoptosis (Vignali 2008). Additionally, other studies have suggested that Tregs 
have cytolytic activity and can directly eliminate target cells via granzyme/perforin 
dependent way  (Gondek et al. 2005, Cao et al. 2007). Furthermore, generation 
of pericellular adenosine nucleosides by coexpressed CD39 and CD73 on Tregs 
was shown to suppress activated effector T cell function via type 1 purinergic 
adenosine A2A receptor expressed on effector T cells (Deaglio et al. 2007). On 
the other hand, others have suggested that an indirect way of immunological 
suppression by inhibiting APC (such as DCs) maturation and/or function that 
could potentially attenuate effector T cell activation by DCs (Tang and Bluestone 
2006, Tang et al. 2006). Moreover, Tregs secrete IL-10 and TGF-β inhibitory 
cytokines suppressing effector T cells while generating Tr1 and Th3 Treg 
subpopulations, respectively (Chen and Wahl 2002, Vignali 2008). Additionally, 
IL-35 was also described as an inhibitory cytokine secreted by Tregs contributing 
in their suppressive function (Collison et al. 2007). In summary, Tregs can 
potentially exert their suppressive effect on effector T cells either directly or 
indirectly via a variety of mechanisms however, whether all these mechanisms 
are critical for Treg function is still unclear. Concluding, Tregs are capable of 
modulating immune responses that are deleterious to the host as well as playing 
an indispensable role in the regulation of autoreactive T cells and prevent 
autoimmune diseases (DiPaolo et al. 2005, Sakaguchi et al. 2008). Impairment in 
either the development or function of Tregs seems to be the primary cause of 
autoimmune and inflammatory diseases in both humans and animals (Sakaguchi 
et al. 2008).  
1.6 The Non-obese diabetic mouse 
1.6.1 Model of Type 1 Diabetes 
In 1974 at the Shionogi Research labs in Japan, a mouse strain now known as 
non-obese diabetic (NOD) mouse, was developed as a model for T1D in which 
autoreactive cells such as CD8+ CTLs target the insulin producing β cells 
(Hanafusa et al. 1994, Makino et al. 1980, Lieberman et al. 2003). Since then, 
NOD mice have become a well described mouse model used for understanding 
human T1D as they share various genetic and immunologic traits with the human 
form ofT1D (Hanafusa et al. 1994, Thayer et al. 2010). NOD mice are genetically 
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predisposed to spontaneously develop T1D in a series of well described 
chronological stages referred in this document as sensitisation, regulation and 
aggression stages. In brief, during the sensitisation stage around 3-4 weeks of 
age the initial priming of autoreactive naive anti-β cell T cells occurs, which takes 
place in the pancreatic lymph nodes (PLNs) (Gagnerault et al. 2002). 
Subsequently, from 3-4 weeks of age, non deleterious infiltration of lymphocytes 
in the pancreatic islets of Langerhans known as insulitis occurs (Faveeuw et al. 
1994) and during the regulation stage between 5-12 weeks of age insulitis of 
autoreactive cells carries on however, their destructive functions are suppressed 
by transient regulatory mechanisms that prevents attack to the host’s β cells 
(Gagnerault et al. 2002). Once the exerted self-tolerance by the regulatory 
mechanisms breaks down around 12 weeks of age, activated CD8+ T cells 
differentiate into CTLs that target β cells and results in their destruction and the 
onset of diabetes, hence referred to as aggression stage (Bach 1995, Delovitch 
and Singh 1997, Cnop et al. 2005).  
 
Among other rodent models used for research of T1D such as biobreeding (BB) 
rats that also spontaneously develop T1D (Kolb et al. 1986) and LEW.1AR1/-
iddm rats as well as other chemically induced models of T1D, NOD mice are the 
most commonly used autoimmune model for T1D where females predominantly 
develop diabetes in comparison to male mice. Once NOD mice are overtly 
diabetic, they lose weight fast and insulin injections are vital for their survival 
(King 2012). Furthermore, MHC-class II gene variants which are major loci in 
both human and NOD mice in the disease process, are conserved (Todd and 
Wicker 2001). In summary, although NOD mice have a significantly different islet 
histopathology compared to humans with T1D, they still share several similar 
genetic and immunological characteristics. Therefore, NOD mice have been 
useful in studying the etiopathogenesis of T1D by dissecting pathways and 
mechanisms, providing insights to the human disease (In't Veld 2014). 
 
1.6.2 Initiation of Type 1 Diabetes and insulitis 
The exact cause of T1D is unknown. However, it is speculated that susceptibility 
genes in combination with environmental factors (such as viruses) trigger the 
onset of T1D pathogenesis (Filippi and von Herrath 2008, Van Belle et al. 2011). 
In addition, both the innate and adaptive immune system seem to play a role in 
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the initiation of T1D via PRR binding that leads to upregulation and secretion of 
proinflammatory cytokines and chemokines and ultimately activates T and B cells 
in an effort to eliminate the virus which leads to pancreatic inflammation and 
subsequently the onset of T1D (Green and Flavell 1999, Zipris 2011). 
Furthermore, self-antigens such as insulin, glutamic acid decarboxylase (GAD), 
tyrosine phosphatase-like proteins insulinoma antigen-2 and 2β (IA-2 and IA-2β) 
as well as imogen-38 and islet-specific glucose-6-phosphatase catalytic subunit-
related protein (IGRP), seem to be involved in the initial lymphocyte responses 
against β islets in T1D  (Green and Flavell 1999, Roep and Peakman 2012). 
Under normal conditions, these autoantigens would not be exposed to immune 
cells, yet in T1D are uncovered as a result autoreactive cells can become 
activated in response to autoantigens and initiate an autoimmune response. One 
of the hypothesis explaining the exposure of self-antigens is, followed by viral 
infections, apoptotic events of the islets take place which releases islet self-
antigens and potentially enhances self-antigen presentation by APCs (Filippi and 
von Herrath 2008, Morse and Horwitz 2017). However, recently another study 
suggested that exposure to sequestered self-antigens is not adequate to mount 
T1D (Ono et al. 2017). Therefore, both genetic predisposition as well as 
environmental factors, seem to play an important role in T1D induction. 
 
Until around 3-4 weeks of age there seems to be no abnormal lymphocytic 
infiltration in the islets (Gagnerault et al. 2002). However, subsequently to the 
sensitisation stage, non-destructive or benign insulitis occurs, where initially 
APCs such as DCs and macrophages start invading the edges of islets known as 
peri-insulitis, which are then followed by CD4+ and CD8+ T cell and B cell 
invasion (Thomas and Kay 2000, Brodie et al. 2008). Gradually immune cells 
infiltrate within the pancreatic islets during the pre-diabetic stage. At this point 
during insulitis it is speculated that tolerance is lost towards β cell antigens 
leading to β cell destruction by activated CD8+ CTLs (André et al. 1996, Brodie et 
al. 2008). This pathogenesis of infiltrated islets by APCs, CD8+ T cells capable of 
differentiating into CTLs and other lymphocytes observed in NOD mice, was also 
observed in pancreatic samples of diabetic patients which allows to gain some 
insight of the human disease using NOD mice instead (Hanafusa and Imagawa 
2008). 
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1.6.3 Beta cell destruction 
Following non-destructive insulitis, β cells begin to be destroyed by aggressive 
autoreactive immune cells. In both NOD and human pancreatic islets, β cell 
destruction is thought to be mediated by CD8+ CTLs (Thomas and Kay 2000, 
Hanafusa and Imagawa 2008, Brodie et al. 2008). By the end of this process, 
hardly any β cells survive (In't Veld 2014)  
1.7 T cell and B cell involvement in Type 1 Diabetes 
1.7.1 T cell involvement 
T cells pathogenic role has been well established in T1D where ultimately 
autoreactive T cells infiltrate the pancreatic islets of Langerhans and destroy 
insulin-producing β cells (Roep 2003). In addition, both pathogenic CD4+ and 
CD8+ T cells play distinct roles in mediating diabetogenesis. In regards to CD4+ T 
cells, as mentioned previously, once activated CD4+ T cells can differentiate into 
different subtypes characterised based on their cytokine production and 
immunological function (Alberts et al. 2002, Golubovskaya and Wu 2016). For 
instance, Th1 cells can induce antibodies such as IgG2a/c in mice  as well as 
produce IL-2, IFN-γ, TNF-β amongst others, which activate macrophages that aid 
innate immunity to clear intracellular pathogens (Romagnani et al. 1999, Hollo et 
al. 2000, Stout et al. 2009, Walker and von Herrath 2016), whereas Th2 cells 
produce IL-4 which leads to macrophage activation, IL-5, IL-6, IL-10, IL-13 
amongst others, that are associated with stimulation of the humoral immune 
system which involves the production and secretion of antibodies by B cells 
against extracellular pathogens (Lafaille et al. 1998, Janeway et al 2005, Smith et 
al. 2000). In addition, the secreted products of these Th subtypes can reciprocally 
inhibit the development of the other (Mosmann 1989). Several studies 
documented altered Th1/Th2 balance which has been speculated to be involved 
in the pathogenesis of T1D (Walker and von Herrath 2016). However, there is a 
debate whether T1D is mediated by Th1 or Th2 or even both (Anderson et al. 
1993, Shimada et al. 1996, Azar et al. 1999). Originally, it was proposed that 
autoreactive Th1 cells would promote T1D, whereas Th2 cells would protect mice 
from the disease by dampening the activity of Th1 effectors (Liblau et al. 1995). 
Using T cell cultures expressing diabetogenic TcRs, J. Katz et al. demonstrated 
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that neonatal NOD mice would elicit diabetes when T cells differentiated towards 
Th1 but not Th2 phenotype as Th1 cells actively promoted diabetes (Katz et al. 
1995). Consistent with this concept, IFN-γ that is produced by Th1 cells seemed 
to be particularly involved in the disease process. For instance, progression of 
T1D in NOD mice was directly correlated with increase in IFN-γ levels 
(Rabinovitch 1994). Additionally, in virus-induced T1D models such as rat insulin 
promoter (RIP) lymphocytic choriomeningitis virus (LCMV) transgenic mice, IFN-γ 
seemed to be required for the development of insulitis and T1D (von Herrath and 
Oldstone 1997). Blockade of IFN-γ expression seemed to prevent diabetes 
(Debray-Sachs et al. 1991, Campbell et al. 1991), whereas ectopic expression of 
IFN-γ seemed to be adequate to cause development of diabetes in mice 
(Sarvetnick et al. 1988). IFN-γ was also implicated in homing of diabetogenic T 
cells in the pancreatic islets of NOD mice as well as β cell destruction (Savinov et 
al. 2001, Chong et al. 2001, Barral et al. 2006). Nonetheless, although various 
studies support the notion of Th1 bias in T1D, there are studies that disagree. For 
example, some studies claim that β cell destruction was mediated by Th2 cells 
rather than Th1 cells or that both subtypes are involved (Anderson et al. 1993) 
(Azar et al. 1999, Poulin and Haskins 2000). Long term cultured Th2 cell clones 
bearing a diabetogenic TcR obtained from diabetogenic Th1 cell clones, were 
demonstrated to rapidly cause diabetes in neonatal NOD mice (Poulin and 
Haskins 2000). Moreover, deficiency in IFN-γ or the β chain of its receptor did not 
seem to prevent insulitis or diabetes development in NOD mice (Hultgren et al. 
1996, Serreze et al. 2000). Additionally, IL-4 which promotes Th2 generation, 
was demonstrated to prevent evolution of insulitis (Rapoport et al. 1993, Mueller 
1996). However, deficiency of IL-4 using IL-4 KO NOD mice as well as 
recombinant IFN-γ injection, did not seem to accelerate or intensify insulitis 
(Satoh et al. 1989, Wang et al. 1998). Furthermore, paradoxically to the previous 
notion of a deleterious effect of IFN-γ in T1D, DO. Sobel et al. suggested that on 
the contrary IFN-γ could inhibit the diabetic process in NOD mice by decreasing 
the activity of effector cells against islets (Sobel et al. 2002). Collectively, these 
data suggest that the involvement of Th cells in T1D is much more complex than 
what was previously believed.  
 
Following the discovery of Th17 cells and their secretion of IL-17 (Park et al. 
2005, Harrington et al. 2005), the Th1 paradigm was challenged as Th17 cells 
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were proposed to be involved in T1D pathogenesis. However, the role of Th17 in 
T1D is unclear. Initially IL-17 was speculated to be associated in the pathogenic 
process of T1D (Jain et al. 2008, Emamaullee et al. 2009), yet a subsequent 
study by J. Joseph et al. in which IL-17 was silenced by RNA interference, 
suggested that IL-17 was dispensable in the pathogenesis of T1D and did not 
protect NOD mice from the disease (Joseph et al. 2011). Moreover, interestingly 
further investigations by MA. Kriegel et al., II. Ivanov et al. and K. Lau et al., 
suggested that IL-17 could protect T1D murine models from T1D or even delay 
T1D development than promoting T1D (Ivanov et al. 2009, Kriegel et al. 2011, 
Lau et al. 2011). Interestingly, in the gut of patients with Crohn’s disease, cells 
capable of expressing both IL-17 and IFN-γ were identified and subsequently 
observed in the colon of an adoptive cell transfer mouse model (Annunziato et al. 
2007, Ahern et al. 2011). These cells sometimes referred to as Th1/17 cells, were 
suggested to be present in the T1D setting according to L. Reinert-Hartwall et al. 
who observed in T1D children IL-17+ cells to have a higher predisposition in 
making IFN-γ in comparison to healthy controls (Reinert-Hartwall et al. 2015). 
Similarly, separate studies using T1D patients, also implicated Th1/17 cells in 
T1D (Honkanen et al. 2010, Ferraro et al. 2011, Arif et al. 2011). More recent 
evidence suggest that Th17 cells have distinct plasticity depending on the 
inflammatory setting (Hirota et al. 2011). Nonetheless, further investigations are 
required to clarify the role of Th1, Th2 and Th17 in the pathogenesis of T1D.  
 
Furthermore, more recently another T cell subtype that is speculated to be 
involved in T1D development is the follicular helper T (Tfh) cells that provide 
assistance in B cell activation and ultimately antibody production (Vinuesa et al. 
2005). Using a transgenic mouse model in order to investigate the gene 
expression profile of islet-specific T cells via microarray analysis, identified a 
signature of Tfh cell differentiation. In addition, purified memory T cells from T1D 
patients seemed to have higher mRNA levels of Tfh cell markers such as 
CXCR5, ICOS, PDCD1, IL-21 as well as BCL6 that is a master transcription 
factor for Tfh cell differentiation, in comparison to healthy controls (Kenefeck et 
al. 2015). Data from mouse models provided evidence which suggest that Tfh 
cells are partly responsible for T1D pathology. For instance, Roquin is a gene 
that when expressed Tfh cells are generated and when mutated formation of Tfh 
cells is exaggerated resulting in systemic autoimmunity (Vinuesa et al. 2005). 
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Using a TcR transgenic diabetes mouse model, mutation of Roquin gene not only 
caused immoderate formation and activity of Tfh cells but also fast progression to 
T1D (Silva et al. 2011). Overall, it has been illustrated that an expansion of cells 
with Tfh phenotype seem to be a T1D characteristic in both mouse models and 
humans (Walker and von Herrath 2016).  
 
In T1D autoreactive CD8+ T effector cells have been established to play a 
fundamental role in targeting and subsequently eliminating pancreatic β cells. 
Various investigations using the NOD mouse have contributed in the 
understanding of the mechanisms involved in the activation, homing and β cell 
destruction attributes of CD8+ T effector cells (Tsai et al. 2008). For instance, 
pancreatic islets of recently diagnosed T1D patients were significantly infiltrated 
with CD8+ T cells which suggested that CD8+ T cell were involved in the onset of 
T1D (Hänninen et al. 1992, Itoh et al. 1993). Studies using NOD mice in order to 
elucidate the contribution of CD8+ T cells in T1D pathogenesis provided evidence 
which suggested that both CD4+ and CD8+ T cells were required in 
diabetogenesis (Bendelac 1987, Yagi et al. 1992, Christianson et al. 1993, 
DiLorenzo et al. 1998). This conclusion was assessed via adoptive transfer 
studies in which the ability to transfer diabetes of each NOD T cell subset into 
neonatal NOD and severe-combined immunodeficient NOD (NOD.scid) was 
compared. For example, diabetes was induced less efficiently when only splenic 
CD4+ T cells were transferred from female prediabetic NOD mice into NOD.scid 
mice in comparison to co-transfer of both CD4+ and CD8+ splenic T cells that 
induced diabetes more efficiently (Christianson et al. 1993). Similarly to this 
notion, NOD islet-derived β cell-specific CTL clones seemed to be able to 
transfer diabetes especially when co-injected with unstimulated polyclonal CD4+ 
T cells (Nagata et al. 1994, Utsugi et al. 1996). In addition, beta 2-microglobulin 
(beta2m)-deficient NOD mice lacking MHC-class I molecule therefore no 
generation of CD8+ T cells, did not develop T1D (Sumida et al. 1994, Serreze et 
al. 1994). Moreover, interactions between CD8-APCs or CD8-β cells seem to 
contribute in T1D development as NOD mice lacking MHC-class I on either 
mature APCs or β cells, never became diabetic (Hamilton-Williams et al. 2003, de 
Jersey et al. 2007). Collectively CD8+ T cells are crucial contributors of T1D 
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progression as they have been implicated in both early and late stages of the 
disease.  
 
1.7.2 B cell involvement 
B cells seem to play a vital role in T1D onset although it is considered to be a T 
cell-mediated autoimmune disorder (Hinman and Cambier 2014).  For example, 
in 1996 D.V. Serreze et al. generated B cell deficient NOD mice that seemed to 
be resistant to T1D. These mice had a functionally inactivated Ig μ heavy chain 
and therefore were unable to generate B cells. This strain of mice was known as 
NOD.Ig μ null, they retained all known susceptibility genes of T1D and although 
they lacked B cells they had normal numbers of T cells (Serreze 1996). Later on, 
H. Noorchashm et al. induced in vivo depletion of B cells using anti-Ig μ antibody 
in female NOD mice and demonstrated abrogation of insulitis and sialitis 
development in contrast to control mice. In addition, they found that 
discontinuation of anti-Ig μ antibody treatment resulted repopulation of B cells 
and re-appearance of insulitis and sialitis (Noorchashm et al. 1997). Subsequent 
studies with various methods depleting B cells in NOD mice, for instance using 
anti-CD20 (Hu et al. 2007), anti-CD22 (Fiorina et al. 2008), blocking BAFF (a vital 
B cell survival factor) using BCMA-Fc (Mariño et al. 2009) or anti-BAFF 
monoclonal antibodies (mAbs) (Zekavat et al. 2008), results in similar protective 
effects against T1D. Similarly in newly diagnosed T1D patients, the use of 
rituximab results in depletion of B cells as well as transient preservation of β cell 
function (Pescovitz et al. 2009). Further evidence also suggested that the BcR 
may change the development of T1D in mice depending on the specificity against 
islet antigens of the BcR repertoire produced (Hulbert et al. 2001). Based on 
several studies it was speculated that B cells antibody production, cytokine 
secretion and auto-antigen presentation properties are implicated in T1D 
pathogenesis (Hinman et al. 2014). For instance, in regards to antibody 
production, although autoantibodies against islet antigens were detected in early 
stages of T1D and correlated in T1D pathogenesis, autoantibodies do not seem 
to play a primary diabetogenic role of B cells as transfer of autoantibodies from 
diabetic NOD mice to NOD.Ig μ null mice did not alter their disease protection 
(Serreze et al. 1998, Côrte-Real et al. 2009). In regards to B cell antigen 
presenting function, in order to investigate the contribution of antigen 
presentation versus autoantibody production, F. S. Wong et al. used transgenic 
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NOD mice that expressed IgM heavy chain yet were unable to to secrete 
antibodies. In comparison to B cell deficient NOD mice, the transgenic NOD mice 
exhibited an increased incidence of T1D in comparison to B cell deficient NOD 
mice, indicating that specific antigen presenting function of B cells was 
implication in diabetogenesis (Wong et al. 2004). Further to this, it was 
speculated that B cells were essential for the initial T cell priming to pancreatic β 
cell GAD self-antigen, as transfer of NOD B cells into B cell deficient NOD mice 
restored T cell responses against GAD that were absent in B cell deficient NOD 
mice (Serreze et al. 1998). Interestingly, another study suggested that B cells are 
not a prerequisite for T1D in NOD mice. This was speculated as subsequently to 
T cell transfer from NOD mice into NOD.scid mice that lacked functionally mature 
T and B cells and usually do not develop T1D, still developed insulitis and 
ultimately T1D although they lacked B cells (Charlton et al. 2001). Nonetheless, 
this could be explained by a seeming ability of other subpopulations of APCs 
such as macrophages and DCs, to elicit a T cell response against GAD following 
initial priming by processing and presenting GAD, yet less efficiently (Serreze et 
al. 1998). Furthermore, both MHC-class I and II have been suggested to be 
involved in diabetogenic T cell activation as deficiency in either MHC-class I or II 
of B cells in NOD mice have been observed to result in a decrease of activated 
CD8+ T cells or resistance to T1D, respectively (Noorchashm et al. 1999, 
Stratmann et al. 2000, Marino et al. 2013). Collectively, up to date, evidence 
support the notion of antigen presenting function of B cells being their primary 
pathogenic action in T1D. 
1.8 Regulatory T cell overview in Type 1 Diabetes 
Since the discovery of Tregs (see section 1.5), various studies have speculated 
their vital involvement in T1D among other autoimmune diseases (Paschou 
2011). In regards to T1D, despite the ongoing infiltration of pancreatic β cells by 
several immune cells prior to the onset of diabetes, overt diabetes does not occur 
until months later. This suggested that peripheral immunoregulatory mechanisms 
keep autoreactive T cells in check yet due to progressive breakdown of those 
mechanisms results in part to T1D progression. Initial evidence from co-transfer 
studies indicated the involvement of Tregs in the delay of β cell destruction and 
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disease development. For instance, C. Boitard et al. and colleagues transferred 
splenocytes from diabetic NOD mice into pre-irradiated adult NOD mice as a 
model of accelerated T1D. They then transferred splenocytes from non-diabetic 
donors and observed a delay in disease development. Subsequent depletion 
experiments showed a CD4+ cell-dependent transient protection originating from 
the thymus of non-diabetic donors (Boitard 1989). Similarly, Hutchings and 
Cooke et al. showed that transfer of splenocytes from young non-diabetic NOD 
mice into irradiated recipients followed by a transfer of splenocytes from diabetic 
NOD mice, did not exhibit hyperglycaemia and demonstrated a role of CD4+ cells 
in this protective effect (Hutchings and Cooke 1990). Additionally, later on the 
removal of CD62L-expressing  CD4+ T cells (a marker expressed by Tregs, naive 
and memory T cells) (Fu et al. 2004, Surh 2008, Matsushita 2008) from 
splenocytes of pre-diabetic mice enhanced the generation of diabetogenic 
lymphocytes whereas expression of CD62L exhibited enriched protective or 
suppressive capacity (Lepault et al. 1995, Lepault and Gagnerault 2000). Similar 
effects were observed in NOD mice in which depletion of CD25-expressing T 
cells (the α-chain of IL-2 receptor exressed by Tregs and other activated T cells) 
(Sakaguchi et al. 1995, Asano et al. 1996) or disruption of a crucial pathway 
involved in Treg development, B7/CD28 pathway in NOD mice would result in 
acceleration of T1D onset (Suri-Payer et al. 1998, Salomon et al. 2000, Tang et 
al. 2003). Moreover, Z.Chen et al. using Foxp3-deficient NOD mice documented 
an accelerated onset of destructive insulitis and therefore T1D progression that 
again illustrated a role of Tregs in T1D pathogenesis (Chen et al. 2005). Further 
to this, adoptive transfer of ectopic Foxp3-transduced T cells with islet antigen 
specificity reversed the disease of recently developed diabetic mice (Jaeckel et 
al. 2005). However, despite the known suppressive Treg mechanisms discussed 
in section 1.3, the exact mechanism(s) involved in this protection against the 
development of the disease, is unclear.  
 
Following the established Treg involvement in T1D, subsequent mounting 
evidence supported the notion of either quantitative and/or qualitative defects in 
Tregs during T1D development. Therefore, the disease progression is speculated 
to be in part due to an imbalance in either the number and/or function of Tregs 
towards autoreactive effector T cells (Cabrera et al. 2012). For instance, in 
regards to Treg function, S. Gregori et al. suggested an age-dependent decline in 
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Treg suppressive activity as co-transfer of Tregs and splenocytes depleted of 
Tregs from 8 week old NOD mice into NOD.scid mice delayed the onset of 
diabetes, whereas co-transfer of the same populations from 16 week old NOD 
mice did not (Gregori et al. 2003). Additionally, S. You et al. suggested that 
decline of Treg suppressive activity does not solely explain the onset of T1D. 
Instead, he also suggested a possible progressive resistance of autoreactive 
effector T cells against the inhibitory activity of TGF-β that is secreted by Tregs 
and in combination with Treg activity decline could result in T1D progression (You 
et al. 2005). Further to this, M. Tritt et al. also supports the notion of a qualitative 
rather than a quantitative change in Tregs of NOD mice as they demonstrated an 
age-dependent decline of Treg functional potency (Tritt et al. 2007). Qualitative 
changes of Tregs have also been observed in T1D patients (Kukreja et al. 2002, 
Brusko et al. 2005, Lindley et al. 2005). Interestingly, R.J. Mellanby et al. 
suggested that there is no qualitative change in the in vitro Treg suppressive 
activity of diabetic NOD mice towards effector T cells in comparison to Tregs from 
non-diabetic NOD mice. In addition, following cotransfer of Tregs and effector T 
cells into NOD.scid mice, although they documented a decline in Treg 
suppressive activity they speculate that this does not indicate a decline in Treg 
function as contamination from non-Foxp3+ populations could skew the results 
(Mellanby et al. 2007). On the other hand, some studies support the notion of a 
quantitative change in Tregs as well, that contributes in T1D development. For 
instance, S.M. Pop et al. demonstrated a temporal percentage decline of islet 
infiltrating CD4+ CD25+ CD62Lhi T cells as well as FoxP3 and TGF-β co-
expressing T cells inside pancreatic lymph nodes in combination with an age-
dependent decline of these Treg populations TGF-β suppressive activity (Pop et 
al. 2005). Further to this, B.K. Nti et al. suggested that migration of Tregs in PLNs 
might play a potential role in diabetogenesis as they documented a decrease in 
PLN Treg numbers of NOD mice possibly due to the downregulation of relative 
chemokines such as SDF-1 (Nti et al. 2012). In addition, R.K. Gregg et al. 
documented an abrupt decline of membrane-bound TGF-β Tregs alongside with 
decline in their suppressive function during the transition from benign insulitis to 
deleterious insulitis and diabetes onset (Gregg et al. 2004). In contrast, other 
studies support no alterations of primary and secondary lymphoid tissue Treg 
frequencies in an age-dependent manner (Tritt et al. 2007) threrefore, we cannot 
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arrive at a consensus as to whether diabetes is associated with changes in Treg 
numbers.  
 
In regards to the thymus, thymic development of Tregs in NOD mice seems to be 
normal (Sgouroudis and Piccirillo 2009, Dardenne et al. 1989) if not enhanced 
(Feuerer et al. 2007). Assessing the frequency and function of thymic Foxp3-
expressing nTregs in NOD mice and non-diabetes prone control mice, M. Tritt et 
al. suggested that there are no alterations in either the frequency or function of 
nTregs in the thymus of pre-diabetic NOD mice (Tritt et al. 2007). However, A.J. 
Wu et al. demonstrated a decrease in thymic Tregs of NOD mice characterised 
as CD4+ CD25+ in comparison to non-diabetes prone mice that may however be 
explained by the reduced thymus size of 3 week old NOD mice that potentially 
resulted in reduction of all thymocyte populations including Tregs (Wu et al. 
2002). In comparison to more recent evidence provided by J. Tellier et al., they 
documented an increase in frequency of thymic Foxp3-expressing Tregs (Tellier 
et al. 2013). Additionally, T.M. McCaughtry et al. used RAG2p-GFP reporter mice 
in order to distinguish between thymic Foxp3-expressing Tregs that have been 
newly developed (ND) or Tregs that are present in the thymus subsequent to 
their development (referred to as resident Tregs in this document) which adds 
another layer of complexity in Treg analysis (McCaughtry et al. 2007). In brief, 
GFP is coexpressed when RAG genes are active during TcR rearrangement and 
although GFP transcription terminates with RAG activity, GFP protein levels 
gradually decline as its half-life is estimated to be ~56 hours in conventional 
CD4SP thymocytes (Mombaerts et al. 1992, Monroe et al. 1999, McCaughtry et 
al. 2007). Therefore, this system would allow examination of thymic ND and 
resident Tregs, which have been neglected by previous studies investigating 
Tregs in T1D. 
1.9 Project aims 
Numerous investigations undertaken to understand the involvement of Tregs in 
T1D pathogenesis, lead to the mounting contradictory evidence in regards to 
thymic and peripheral Treg function and/or number using different T1D mouse 
models at various stages of the disease. We hypothesise a loss of Tregs in pre-
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diabetic NOD mice that may be correlated with T1D progression. Therefore, due 
to the contradictory findings and the importance of Tregs in T1D development, 
this project aimed to reinvestigate the development and proliferative homeostasis 
of thymic Tregs as well as the proliferative homeostasis of Tregs in secondary 
lymphoid tissues, using for the first time RAG-GFP expressing NOD mice in order 
to dissect any alterations in ND and resident Tregs that have not been taken into 
account by previous studies. 
 
These are the main questions that this project aimed to investigate: 
 
1) Are there any alterations in the Treg proportion/number between NOD 
and non-diabetes prone mice, if so, is it age-dependent? 
 
2) Do B cells affect Treg development or homeostasis in NOD mice?  
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Materials and Methods 
2.1 Animals 
  
C57BL/6 (B6), NOD, NOD-RAG2p-GFP, NOD.μMT-/--RAG2p-GFP, Friend Virus 
B (FVB)-RAG2p-GFP mice were used in this project. 
 
Diabetes incidence in our female NOD mouse colony is 95%, approximately 3% 
of mice develop T1D at 12-14 weeks of age, 85% at 18-20 weeks of age with the 
remaining 7% of females progressing to T1D by 23 weeks of age. Animals not 
diabetic by 23 weeks of age rarely develop T1D. The data is based on a cohort of 
200 animals. These statistics highlight that 12-14 weeks of age in our colony 
represents late insulitic-preultimate diabetic stage, a critical time when 
immunoregulation of the autoreactive response starts to breakdown. Thus, in our 
initial studies we focused on two major time points; the pre-early insulitic phase 
(4-6 weeks) and the post-insulitic/pre-diabetic phase (12-14 weeks) to assess 
Treg proportions in primary and secondary lymphoid tissues. 
 
C57BL/6 mice were provided by the Biomedical Services Facility, University of 
York. FVB-RAG2p-GFP mice (hereafter referred to as FVB-RAG-GFP) were 
purchased from the Jackson Laboratory and thereafter supplied by the 
Biomedical Services Facility, University of York. FVB-RAG2p-GFP mice have 
been described previously by Yu et al. 1999 and used by McCaughtry et al. (Yu 
et al. 1999, McCaughtry et al. 2007). NOD-RAG2p-GFP reporter mice (hereafter 
referred to as NOD-RAG-GFP) were a product of FVB-RAG2p-GFP mice 
backcrossed 12 generations (N12) to the NOD mouse. NOD.μMT-/- -RAG2p-GFP 
reporter mice (hereafter referred to as B-KO) were a product of N12 NOD-RAG2p-
GFP mice crossed with NOD.μMT-/- resulting in heterogeneous mice which were 
backcrossed with NOD.μMT-/- in order to get a homogeneous colony. Mouse 
genotypes were determined by flow cytometric analysis of blood samples to 
assess B-cells and/or GFP presence depending on the strain of mouse. Unless 
otherwise stated in the results, slightly younger adult female mice used for 
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experimental purposes were between 8 and 14 instead of 12 and 14 weeks of 
age due to time limitations, yet still representing late insulitic-preultimate diabetic 
stage, and were closely age matched within experiments. 
 
All animals were bred and maintained under specific pathogen-free barrier 
conditions, under a 12 hour light/dark cycle and fed normal chow at the Biological 
Services Facility, University of York. All experimental procedures were conducted 
in accordance with UK Home Office and ARRIVE regulations 
(https://www.nc3rs.org.uk/arrive-guidelines). 
 
2.2 Cell preparation 
 
Single cells were prepared from the thymus, spleen and lymph nodes. For the 
thymus, the tissues were removed and either homogenised or digested with 
digestive enzymes. For homogenisation thymi were placed in an 100µm 
EASYstrainerTM (Greiner bio-one) on top of a 50 ml falcon tubes and the tissue 
was pressed through the strainer using a plunger from a 5 ml syringe.  The cells 
were resuspenced in 15 ml of 1X phosphate buffered saline (PBS)/1% FCS. For 
digestion, isolated thymi were transferred into a 24 well plate containing 500 µl of 
digestion media (RPMI supplemented with 0.325 Wunsch U/ml Liberase TM and 
50 Kunitz/ml DNAseI) and then cut into small pieces (+/- mm3). The tissue pieces 
were transferred with the digestion media to a 50ml falcon tubes, placed in a 
shaker for 50 minutes at 1800 rpm at 37o, then 10 µl of 50 nM stock 
concentration of ethylenediaminetetraacetic acid (EDTA) with a final 
concentration of 1.96nM, was added for 5-10 minutes on ice to dissociate the 
suspension into single cells. 
 
For the spleen, the single cells were prepared by homogenising as above. For 
both the thymus and spleen red blood cells were removed. The single cell 
suspensions were centrifuged at 300g for 10mins, 40C and cell pellets 
resuspended in 1 ml of ACK lysing buffer (Gibco) for 1 minute for the thymi and 5 
minutes for the spleens. 30 ml of 1X PBS/1% FCS was added to each tube and 
the cells were then centrifuged as before, supernatant discarded and the cells 
were resuspended in 1 ml 1X PBS/1% FCS as appropriate for subsequent 
procedure.  
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For the lymph nodes, single cells were prepared by grinding the lymph nodes 
between two frosted glass slides (Thermo scientific). Single cells were then 
resuspended in 500 µl of 1X PBS/1% FCS. 
Following the preparation of single cell suspensions, a small volume of the 
samples was stained with 1:20 dilution of Triton blue (cell suspension:Triton 
blue). Thymic and splenic cell numbers were measured automatically using a live 
cell imaging chamber ViCell and the cell number of lymph nodes was counted 
manually using a haemocytometer. All cell sample data were acquired using 
Becton Dickinson Fortessa X-20 with 4 lasers and 16 detectors and subsequently 
cell sample analysis was done using FlowJo software. 
 
2.3 Flow cytometry 
 
Single cells prepared as in Section 2.2, were resuspended in x1 PBS/1% FCS. 
Then 100 µl of cell suspension (equivalent to 106 to 107 cells) was transferred to 
an appropriate vessel and CD16/CD32 (Fc block) antibodies added for 20 
minutes at 4oC in order to block the Fc receptors. The cells were then centrifuged 
for 7 minutes at 300g, the supernatant discarded and the cell pellets were 
resuspended in 100 µl 1X PBS/1% FCS. Subsequently, surface molecules were 
incubated with appropriate fluorescently labelled antibodies and incubated for 30 
minutes at 4oC in the dark. All antibodies used in this study were assessed and 
optimised for use against isotype control. A list of antibodies used is shown in 
Table 2.1. Following incubation, the cells were then washed 2X as before and 
resuspended in 500µl 1X PBS/1% FCS ready for analysis.  
 
For detection of intracellular Foxp3 detection, surface molecules were stained as 
above, the cells were centrifuged as before and resuspended in 
fixation/permeabilisation buffer (eBioscience) overnight at 40C. The next day, the 
cells were washed 2X in 1X permeabilisation buffer (eBioscience) then incubated 
with fluorochrome labelled Foxp3 antibodies for 1 hour at room temperature. The 
cells were washed 2X in permeabilisation buffer then resuspended in 100 µl x1 
PBS/1% FCS ready for analysis. 
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For dual detection of GFP and Ki67, the surface molecules were stained as 
above and the cells centrifuged as before. The cells were fixed, permeabilised 
and incubated with Ki67 as for the Foxp3 staining protocol above. Following this, 
the cells were centrifuged and cell pellets resuspended in 200 µl of 1x fixation 
buffer (Biolegend) for 10 mins at room temperature. A dual fixation was required 
in order to detect GFP as a single fixation protocol with the eBioscience 
fixation/permeabilization buffer instead of the Biolegend fixation buffer, resulted in 
no detection of GFP. The cells were then centrifuged as before and washed 2X in 
1X permeabilisation buffer (Biolegend). The cell pellet was resuspended in 200 µl 
of 1x Perm buffer (eBioscience) containing fluorochrome-labelled anti-GFP 
antibodies 1 hour incubation at 4oC in the dark. Anti-GFP was required in order to 
detect effectively GFP-expressing cells. Following incubation, the cells were 
washed 2 times with 200 µl of Perm buffer (Biolegend) and then washed twice in 
200 µl 1x PBS/0.5% BSA before resuspending them in 100 µl 1x PBS/0.5% BSA 
to be analysed. 
 
Antibody clones and suppliers are shown in Table 2.1. 
 
Antibody target Fluorochrome Clone Supplier 
CD4 Brilliant Violet 650™(BV650)  RM4-5 Biolegend 
CD8 eFluor 450™/Allophycocyanin (APC) 53-6.7 eBioscience 
CD16/32 ------- 93 eBioscience 
CD25 PerCP-Cyanine5.5 PC61.5 eBioscience 
Foxp3 Phycoerythrin (PE)/eFluor 450™ FJK-16s eBioscience 
GITR Phycoerythrin-Cyanine dye 7(PE-Cy7) DTA-1 eBioscience 
Anti-GFP Alexa Fluor 488 FM264G Biolegend 
Ki67 Phycoerythrin (PE) B56 BD Pharmingen 
LiveDead eFluor 780™ ------- Invitrogen 
 
Table 2.1: Antibody conjugated fluorochromes, clones and suppliers. 
 
2.4 Preparation of cell extracts 
Single cells were prepared from the thymus by homogenisation as before. Cell 
extraction protocol adopted from the splenic extraction protocol by T. Yi et al. (Yi 
et al. 2012). Each thymus mashed in separate 15 ml tubes was then centrifuged 
for 10 minutes at 300g in order to collect all the cells at the bottom of the falcon 
tube, supernatant was then discarded, and the pellet was resuspended in 1 ml 1x 
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PBS/0.5% BSA and then centrifuged for an additional 15 minutes at 3000g at 4oC 
in order to lyse the cells and separate the lysates from the cell extracts. 
Therefore, the extracted protein came from the same number of thymocytes for 
each sample. The supernatant was then removed to a new eppendorf tube and 
stored at -20 oC if not used immediately.  
 
2.5 ELISA-IL-2 
 
For the ELISA 100 µl of thymic cell extract was prepared as described above. IL-
2 was detected using an IL-2 ELISA kit with 2pg/mL sensitivity, following 
manufacturer’s guidelines (Mouse IL-2 ELISA Ready-SET-Go!Ⓡ kit from 
affymetrix eBioscience). Briefly, the plate was coated with capture antibodies, 
washed three times with a PBS/1% Tween 20 buffer, the wells were blocked by 
incubation with 1X ELISA/ELISASPOT diluent for an hour at room temperature. 
The IL-2 standard was added and serial 2 fold dilutions performed generate a 
standard curve. Subsequently, 100 µl of the cell extracts were added to 
appropriate labelled wells and incubated at room temperature for 2 hours. 
Following incubation, the plate was washed 2X as before. A biotinylated anti-IL-2 
antibody was added to the wells and incubated for 1 hour at room temperature. 
Following 2X washes as before, an avidin-HRP substrated was added to the 
plate for 30 minutes at room temperature. The plate was washed twice again, 
and bound cytokine detected with TMB solution. Finally, stop solution was added 
to each well prior to reading the plate at 450nm.  
 
2.6 Statistical analyses 
 
All graphs were drawn using GaphPad Prism and statistical analyses (Mann-
Whitney and One way ANOVA Tukey’s tests) were performed using built-in 
functions within the software. 
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Results 
3.1 Type 1 Diabetes and the Thymus 
3.1.1 Alterations of Treg numbers in the NOD mouse 
 
Regulatory T cells (Tregs) have been described previously to play a major role in 
the processes averting autoimmune diseases such as Type 1 Diabetes (T1D) 
(Sakaguchi et al. 1995). As suggested by You, S. et al., T1D progression in NOD 
mice is partly explained by a decline of peripheral Tregs’ activity where others 
claimed that this might be a result of a decrease in peripheral Treg numbers 
instead (Sakaguchi et al. 1995, You et al. 2005). In regards to the thymus, others 
claimed no alteration in thymic Tregs (D'Alise et al. 2008). However, using for the 
first time RAG-GFP reporter mice that could distinguish between newly 
developed and resident Tregs in the thymus, we decided to re-examine the 
thymic Treg proportions and establish a pattern of Treg homeostasis in NOD 
mice in order to enhance our knowledge on T1D pathogenesis and ultimately find 
a cure. Therefore, flow cytometric analysis was used to quantify the thymic total 
Treg population of 5 male C57BL/6 (B6) 8 week old auto-immune free strain used 
as a control, and 4 female NOD 10 week old mice. Over the years Tregs have 
been phenotypically defined to express a variety of cell markers such as CD25, 
CD45RBlo, CTLA-4, CD62L, CD103 and GITR (Powrie et al 1193, Fehérvari and 
Sakaguchi 2004) on their cell surface of CD4 single positive (CD4SP) cells. 
However, some of these molecular markers are not unique to this T cell lineage 
and can be also found on activated, effector or memory T cells as well (Hori 
2003, Zhan et al. 2007). Therefore, initially we decided to look at CD25 that is 
constitutively expressed on the majority of Tregs, and GITR coexpression on 
CD4SP cells in order to be more restrictive in Treg identification than other 
studies that only used CD4 and CD25 coexpression. The final gate of total Treg 
population was defined by gating on the thymic lymphocytes, excluding doublets 
and dead cells, focusing on CD4SP expression and sequential GITR and CD25 
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expression (Fig. 1.1A). Identical gating strategy was applied for both strains, B6 
and NOD (Fig. 1.1B). There was a trend towards increase and a significant 
increase in the frequency and the absolute number, respectively of thymic total 
Tregs of NOD in comparison to B6 (Fig. 1.2A and B). In order to validate that this 
increase in NOD Tregs was not due to an increase in NOD thymic cellularity, we 
counted the absolute number of the total thymic cells as one would expect a 
universal direct increase in lymphocytes with cellularity (Fig. 1.2C). However, 
there was no significant difference in the total thymocyte number between B6 and 
NOD mice (Fig. 1.2C). This indicated that the changes in frequency and absolute 
number of NOD total Treg was due to alterations within the CD4SP population 
rather than changes in total thymic cellularity. 
 
Foxp3, an intracellular transcription factor, was established to be specifically 
expressed in Tregs which allows the sub-classification and detection of precursor 
(pTregs) (GITRhi CD25+ Foxp3- CD4SP) and mature (mTregs) (GITRhi CD25+ 
Foxp3+ CD4SP) Tregs (Williams and Rudensky 2007, Thiault et al. 2015). The 
addition of Foxp3 in our markers panel not only resolved the Treg population 
analyzed from other lymphocytes mentioned above (activated, effector or 
memory T cells), but also allowed analysis of pTregs and mTregs that have been 
neglected in other murine T1D studies. Hence, flow cytometry was used to 
measure the thymic pTregs and mTregs of 5 female B6 and 5 female NOD mice 
of 13 weeks of age, in order to observe whether pTregs or mTregs accounted for 
the increase in NOD Tregs we documented initially. Gating strategy was identical 
to the previous experiment (refer to Fig.1.1A), with the only difference of the final 
gate focusing on the Foxp3 expression of CD4SP CD25+ GITRhi cell population 
instead (Fig.1.3). We were able to replicate the pattern observed in Figure 1.2A 
and B, but in this experiment the increase of total Tregs in NOD mice compared 
to B6 mice was statistically significant in both their frequency and absolute 
number (Fig.1.4A and B). No significant difference was observed in either the 
frequency or the absolute number of pTregs between B6 and NOD mice 
(Fig.1.4A and B). However, there was a significant increase in both the frequency 
and the absolute number of mTregs of NOD in comparison to B6 mice (Fig.1.4C 
and D). Once again, there was no significant difference in the total thymocyte 
number between B6 and NOD mice (Fig.1.4E). This verifies that changes of NOD 
mTregs are not affected due to total thymocyte number difference, but alterations 
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within the CD4SP population. In addition, the total Treg increase in NOD mice 
observed previously (Fig.1.2A and B) is most likely due to NOD mTregs increase 
and not pTreg alterations (Fig.1.4). 
 
3.1.2 Treg development compromised in the NOD-RAG-GFP 
mice 
 
RAG2p-GFP reporter mice have been used to identify novel Treg populations. 
The RAG2p promoter drives GFP expression in RAG2p-GFP mice (Monroe et al. 
1999). RAG genes are active during TcR rearrangement (Mombaerts et al. 1992), 
therefore GFP begins to be coexpressed with RAG expression at the late CD4-
CD8- double-negative stage and throughout the CD4+CD8+ double-positive (DP) 
stage of intrathymic T cell development (Boursalian et al. 2004, Matthews and 
Oettinger 2009). Although GFP transcription terminates immediately after the DP 
stage with RAG activity, the GFP protein has a half-life of ~56 hours in 
conventional CD4SP thymocytes (McCaughtry et al. 2007). Thus, GFP 
expression of RAG2p-GFP mice gradually declines and acts as a “molecular 
timer” of thymocyte maturation (McCaughtry et al. 2007). This allowed the 
identification of newly developed (GFP+) and resident (GFP-) Tregs. However, 
observing these Treg subpopulations in NOD mice has not been examined 
before. To assess whether alterations occurred in these subpopulations, flow 
cytometry was conducted. 
 
Female mice 13-14 weeks of age, 5 FVB and 3 NOD expressing RAG2p-GFP 
(hereafter called FVB-RAG-GFP and NOD-RAG-GFP, respectively), were used 
to observe the GFP expression of total Tregs. Flow cytometric analysis showed 
that the GFP percentage frequency of CD4SP thymocytes was lower than the 
double positive (DP) population yet greater than the double negative (DN) 
population, as predicted as DP thymocytes are actively transcribing GFP 
(Fig.1.5A). For this experiment only the GFP expression of total Tregs (i.e. 
CD4SP CD25+ GITR+) could be quantified, as Foxp3 was not detected using the 
GFP staining protocol. The final gate of GFP- and GFP+ total Treg populations 
was applied for both strains, in which there was a subtle difference in the intensity 
of GFP fluorescence between FVB-RAG-GFP and NOD-RAG-GFP mice 
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observing higher intensity of GFP fluorescence in FVB-RAG-GFP mice than 
NOD-RAG-GFP mice (Fig.1.5B). Nonetheless, in contrast to the significant 
difference observed in total Tregs of B6 and NOD mice (Fig. 1.2), there was no 
significant difference in either the frequency or absolute number of total Tregs 
between FVB-RAG-GFP and NOD-RAG-GFP mice (Fig.1.6 A and B) that could 
be explained either by the use of a different strain as a control or by the slight age 
difference between the mice used depicted in Figure 1.2 and 1.6. C57BL/6 strain 
would have been more appropriate to be used as a control, if there was a 
C57BL/6-RAG-GFP available, due to the fact that FVB-RAG-GFP strain has a 
slightly wider spread as seen in some of our results than C57BL/6 mice. An 
additional reason explaining this non-significance is the fact that a total of only 3 
NOD-RAG-GFP mice were used for this experiment which was due to the limited 
number of mice available at the time, that is insufficient to detect differences 
between the groups. However, there was significant decrease in both the 
frequency and absolute number of newly developed total Tregs of NOD-RAG-
GFP mice compared to FVB-RAG-GFP mice (Fig. 1.6C and D). As mentioned 
earlier, the use of GFP allowed us to distinguish newly developed from resident 
Tregs and based on this we observed a significant increase in the frequency and 
a trend towards increase in the absolute number of resident total Tregs (Fig. 1.6E 
and F) of NOD-RAG-GFP mice. In order to rule out the possibility that these 
alterations were due to changes of the total cell number of the thymocytes, we 
counted the total thymocyte number of both strains. However, the total thymocyte 
number of FVB-RAG-GFP and NOD-RAG-GFP mice did not significantly differ 
(Fig. 1.6G). Therefore, the decrease of newly developed total Tregs observed in 
NOD-RAG-GFP mice is a genuine alteration within the Treg subpopulation that is 
not accounted by a change in thymocyte cellularity. 
 
3.2 Type 1 Diabetes and the Periphery 
 
3.2.1 Tissue-specific Treg alterations 
 
As mentioned previously in Section 1.1, T1D is a chronic autoimmune condition 
in which the destruction of the beta cells situated in the pancreatic islets of 
Langerhans, results in high blood sugar levels due to a paucity of insulin 
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(Daneman 2006, Van Belle et al. 2011). Using Tet-TNFa/CD80 mice, it was 
suggested that accumulation of Tregs in pancreatic lymph nodes (PLNs) during 
the infiltration and insulitis (regulation) stage of T1D, might delay diabetes 
progression in NOD mice (Green et al. 2002). However, other studies using NOD 
mice have observed either a decrease or no alterations in peripheral Tregs 
residing in either the PLNs or the spleen (Wu et al. 2002, Alard et al. 2006) 
(D'Alise et al. 2008, Pop et al. 2005, Nti et al. 2012, Mellanby et al. 2007). The 
RAG-GFP expression in NOD mice provides a means to re-assess these findings 
while looking at Treg GFP expression in secondary lymphoid organs such as 
spleen, ILN and PLN, in addition to the thymus which has not been observed 
before. In order to determine if there was a Treg deficiency among the secondary 
lymphoid organs, flow cytometry was conducted initially using FVB-RAG-GFP 
and NOD-RAG-GFP mice. 
 
To overcome the previous staining issue encountered with Foxp3 and GFP, 
originally for this experiment both precursor/mature Tregs as well as GFP 
expression of those populations, were to be detected using separately α-Foxp3 
and α-GFP antibodies in two distinct plates undergoing different optimal protocols 
depending on the stain (Foxp3 plate and GFP plate).The idea was that in theory, 
the gating strategies applied on the cells stained in each plate, that came from 
the same single cell suspensions but aliquoted in two separate plates, would 
have similar cell frequencies if the same gating strategy was applied on the cells 
from each plate. Therefore, gates identifying Foxp3 expression for instance 
(hence Foxp3 population) from the Foxp3 plate would determine, theoretically, 
the Foxp3 expressing cell population in the GFP plate, that was not stained with 
Foxp3, when similar gating strategy was applied. However, analysis of the data 
obtained using this approach were shown to be unreliable as the results would 
vary among the experiments as a significant amount of Foxp3 expressing cells 
was unintentionally excluded from the final gate. This emphasized the need of an 
optimisation protocol in which both Foxp3 and GFP would be detected 
simultaneously. Therefore, in this experiment only the GFP expression of Total 
Tregs is analysed from the GFP plate (Figure 1.8). 
 
All female mice 9-11 weeks of age 5 FVB-RAG-GFP and 4 NOD-RAG-GFP, were 
used to observe the GFP expression of total Tregs. Data were pooled from two 
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experiments with identical protocol. Figure 1.7 shows the final gating strategy 
(refer to Fig.1.1) of total Treg GFP expression in secondary lymphoid organs. 
There was a significant increase in total Treg frequency of both NOD-RAG-GFP 
spleens and ILNs compared to FVB-RAG-GFP mice, in contrast to their absolute 
numbers where there was no significant difference (Fig.1.8A and B). This 
suggests that alterations within other lymphocyte populations may be occurring 
and not Tregs per se. In agreement to previous findings (Fig.1.6) there was no 
significant difference in either the frequency or absolute number of thymic total 
Tregs (Fig.1.8A and B). There was also no significant difference in either the 
frequency or absolute number of PLN total Tregs between these two strains 
(Fig.1.8A and B). In addition, the mean of the absolute number of PLN total Tregs 
of NOD-RAG-GFP mice is elevated compared to the FVB-RAG-GFP mice 
however, this is not statistically significant (Fig.1.8B). The small number of mice 
used for this experiment could explain the lack of significant difference 
henceforth, the trend of data will be discussed in the upcoming experiments as 
well despite non-significance. There was no significant difference in either the 
frequency or absolute number of total Treg GFP+ of spleens and ILNs (Fig.1.8C 
and D). In contrast to previous findings (Fig.1.6C and D), there was no significant 
decrease in either the frequency or absolute number of thymic ND total Tregs 
(Fig.1.8C and D). However, the mean absolute number of thymic ND Tregs 
seems to be similar to Fig.1.6 D findings. Interestingly, both frequency and 
absolute number of PLN total Treg GFP+ have decreased, yet with significant 
difference only in the frequency (Fig.1.8C and D). The spleen and ILN total Treg 
GFP- frequencies’ trend displayed a non-significant increase yet there was no 
significant difference in their absolute numbers (Fig.1.8E and F). In contrast to 
previous findings (Fig.1.6E and F), there was no significant difference in either 
the frequency or absolute number of thymic resident total Tregs (Fig.1.8E and F). 
Surprisingly, there was no significant difference in either the frequency or 
absolute number of PLN total Treg GFP- (Fig.1.8E and F). In addition, we sought 
to observe whether the genetic background of NOD mice influenced the 
cellularity of the whole organs by quantifying the total cell numbers that could 
potentially account for the alterations documented in Tregs (Fig. 1.8G). Overall, 
these preliminary findings of subtle tissue-specific changes in total Treg 
populations, especially in the PLNs, make one wonder whether is due to 
proliferation, survival and/or B cell interactions. 
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3.2.2 B cells may be involved in Treg alterations in the periphery 
 
B cells seem to play a critical role in T1D. It has been noted that B cell-deficient 
NOD mice are resistant to T1D (Serreze 1996). A variety of ways depleting B 
cells such as: use of anti-CD20 (Hu et al. 2007, Xiu et al. 2008) or anti-CD22 
(Fiorina et al. 2008) in addition to blockage of BAFF, a critical B cell survival 
factor, using BCMA-Fc (Mariño et al. 2009) or anti-BAFF mAb (Zekavat et al. 
2008) has analogous protective effects against diabetes progression in the NOD 
mouse model. Furthermore, B cells also seem to promote pancreatic beta cell 
destruction via insulin-antigen presentation to both CD4+ and CD8+ T cells 
(Mariño et al. 2012). More recently, it was suggested that thymic B cells increase 
Treg numbers (Lu et al. 2015) and our group has also documented that thymic B 
cells accumulate in NOD mice in an age-dependent manner and may contribute 
in the impairment of negative selection of autoreactive T cells (Pinto et al. 
submitted). Therefore, due to insufficient number of investigations whether the 
presence of B cells affects Treg numbers in diabetically-prone mice, we used 
NODuMTKO-RAG-GFP mice for the first time where flow cytometry was 
conducted in order to quantify Treg populations within secondary lymphoid 
organs and the thymus. 
  
A total of 6 female 9-11 weeks of age NODuMTKO-RAG-GFP mice (B-KO), were 
used to observe the GFP expression of total Tregs (Fig.1.8). Data for this 
experiment were combined with previously obtained data from FVB-RAG-GFP 
and NOD-RAG-GFP mice for visual comparison and statistical analysis. All 
protocols were identical. Interestingly, there is no significant difference in the 
frequency of splenic total Tregs between the FVB-RAG-GFP and B-KO mice in 
contrast to the NOD-RAG-GFP (Fig.1.8A). Based on the decrease of total 
splenocytes shown in Fig.1.8 G, a significant decrease of the absolute number in 
total Treg of B-KO mice was also observed which may signify an involvement of 
B cells in the maintenance of splenic Treg numbers (Fig.1.8 B). There was no 
significant difference in either the frequency or absolute number of thymic total 
Tregs among the three strains (Fig.1.8A and B). Similarly to the ILN total Tregs of 
NOD mice, there was also a significant increase in the frequency of ILN total 
Tregs of B-KO mice compared to FVB-RAG-GFP (Fig.1.8A). However, there was 
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no significant difference in absolute number of ILN total Tregs among the three 
strains (Fig.1.8B). There was also no significant difference in both the frequency 
and absolute number of PLN total Tregs among the three strains (Fig.1.8A and 
B). It is difficult to detect a trend in the absolute number of PLN total Tregs due to 
the spread of FVB-RAG-GFP mice. Therefore, repetition of this experiment with 
more mice would clarify whether the absolute number of PLN total Tregs in B-KO 
mice is more similar to the FVB-RAG-GFP mice compared to the NOD-RAG-
GFP. No significant difference was noted in the frequency of total Tregs GFP+ in 
either the spleen, thymus or ILN among the three strains (Fig.1.8C). In contrast, 
the frequency of PLN total Treg GFP+ population was significantly less in both B-
KO and NOD-RAG-GFP mice compared to the FVB-RAG-GFP mice (Fig.1.8C). 
Although there was no significant difference in the absolute number of total Treg 
GFP+ populations of the lymphoid organs depicted in Fig.1.8D, there is a trend of 
decreased total Treg GFP+ cells in both B-KO and NOD-RAG-GFP mice. This 
again could be clarified with the use of more mice. There was also no significant 
difference among the strains in the frequency of total Tregs GFP- in any lymphoid 
organ shown in Fig.1.8E. However, interestingly there seems to be a slight 
difference between the splenic total Treg GFP- B-KO and NOD-RAG-GFP mice 
(Fig.1.8E). No significant difference was observed in the absolute number of total 
Treg GFP- among the strains in the thymus, ILN and PLN (Fig.1.8F). There was 
again an expected significant decrease in the absolute number of splenic total 
Treg GFP- cells in the B-KO mice compared to the other strains (Fig.1.8F). In 
conclusion, these data on B-KO mice have not explained the thymic Treg 
alterations observed previously (Fig.1.3, 1.4 and 1.6) however, they provided 
valuable insights concerning Treg homeostasis in secondary lymphoid organs. 
    
3.3 Thymic Treg alterations not due to interleukin 2 levels 
 
Interleukin 2 (IL-2) is a pleiotropic hormone-like growth factor, which stimulates 
proliferation of activated T cells (Smith and Ruscetti 1981) as well as inducing 
naïve CD4+ T cell differentiation into Tregs (Malek and Castro 2010). Studies 
have demonstrated IL-2 playing a critical role in the maintenance of natural 
immunologic self-tolerance, as the homeostatic maintenance of thymic and 
peripheral CD25+ Foxp3+ CD4+ Treg cells is affected negatively in IL-2 depleted 
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mice (Setoguchi et al. 2005). In addition, low dose administration of IL-2 seemed 
to boost Treg survival in the spleen, PLNs and pancreatic islets and protected 
NOD mice from T1D progression (Tang et al. 2008). Furthermore, our group 
recently showed that ND and resident Treg proportions are affected differently by 
IL-2 availability and that decreased levels of IL-2 only affected resident but not 
ND Treg proportions (Cuss and Green 2012). Regarding B cells, it was 
suggested by Ortega, G et al. that activated B cells express IL-2 receptor (Ortega 
et al. 1984). Therefore, ELISA was used in order to quantify the IL-2 levels in 
RAG-GFP mice; FVB, B-KO and NOD, in order to explain the thymic Treg 
alterations observed previously (Fig.1.3, 1.4 and 1.6). 
 
All female 8-11 weeks of age, 4 FVB-RAG-GFP, 4 NOD-RAG-GFP and 4 B-KO 
mice, were used to quantify the total thymic IL-2 levels. Data obtained using an 
ELISA plate reader depicted in Fig.1.9, showed no significant difference among 
the strains. Hence, changes in IL-2 levels do not appear to explain the thymic 
Treg alterations observed during T1D regulation stage. 
  
3.4 Treg proliferation as a potential rationale for Treg 
alterations in the thymus and the periphery 
 
Ki67 is a protein found in the cell nucleus during the interphase stage and 
sequentially relocates to the surface of condensed chromosomes during mitosis 
yet is absent in quiescent cells (Isola et al. 1990). Based on this it was defined as 
a cell proliferation marker (Starborg et al. 1996). Thymic and/or peripheral Treg 
alterations could be explained based on their proliferation status, therefore flow 
cytometry was conducted in order to quantify Ki67 expression of Treg 
subpopulations in the thymus and secondary lymphoid organs; spleen and PLN. 
All female 11 weeks of age 4 FVB-RAG-GFP, 3 NOD-RAG-GFP and 4 B-KO 
mice, were used for this experiment.  
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3.4.1 Abnormal proliferation of thymic mTregs but not pTregs does not 
explain Treg alterations in NOD mice 
 
Following an optimised protocol, we were able to detect the expression of Foxp3, 
GFP and Ki67 simultaneously on Tregs. This is illustrated on Figure 1.10 in which 
Ki67 is detected clearly in all three groups of mice (FVB-RAG-GFP, NOD-RAG-
GFP and B-KO) (Fig.1.10A) as well as GFP expression of Tregs (Fig.1.10B). 
Although there was no significant difference in either the frequency or absolute 
number of Ki67+ mTregs, that may well be explained by the small number of mice 
used, there is a trend towards an increase in the frequency of proliferating cells of 
B-KO and NOD-RAG-GFP mice (Fig.1.11A and B). In addition, pTregs showed 
no abnormalities in regards to their proliferation status (Fig.1.12 G and H). 
Initially, the total thymocyte number was measured and surprisingly in contrast to 
our previous findings where the total thymus number of B6 and NOD mice were 
similar (Fig. 1.2C and 1.4E), there was a significant decrease in both B-KO and 
NOD-RAG-GFP mice in comparison to FVB-RAG-GFP (Fig.1.11I). Due to the 
fact that data were pooled from different experiments with identical protocol, 
experiment-to-experiment variation may be a major source of variation. Although 
there was no significant difference in either the frequency or absolute number of 
mTregs, there seems to be a slight increase in frequency of B-KO and NOD-
RAG-GFP mice, yet the spread of data and small number of mice mean this is 
not statistically significant (Fig.1.11C and D). There was also no significant 
difference in both the frequency and absolute number of ND mTregs among the 
strains (Fig.1.11E and F). In addition, no significant difference was observed in 
either the frequency or absolute number of resident mTregs among the strains 
(Fig.1.11G and H).  The initial smaller thymocyte number of both B-KO and NOD-
RAG-GFP mice may account for the constant decrease in mTreg (Fig.1.11) and 
pTreg (Fig.1.12) absolute numbers in comparison to FVB-RAG-GFP mice. 
 
3.4.2 B cells may be involved in splenic Treg proportion regulation via 
direct or indirect effect on their proliferation 
 
GFP was not detected in the peripheral Tregs (data not shown) presumably due 
to a change in protocol that required extra staining and washing steps in order to 
include Ki67 and track the proliferation status of peripheral Tregs. As a result, 
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due to the absence of GFP, monitoring of recent thymic emigrants (RTEs) was 
not possible and could only observe total Tregs instead in secondary lymphoid 
organs. However future investigations observing RTEs are imperative as we 
previously observed alterations in RTEs of PLNs (Fig. 1.8C and D). Initially, the 
absolute number of splenocytes was observed to see if there are any defects at 
this level and a significant decrease was noted in B-KO mice compared to FVB-
RAG-GFP and NOD-RAG-GFP mice (Fig.1.13A). There was also a significant 
increase in frequency of both B-KO and NOD-RAG-GFP splenic Tregs in 
comparison to FVB-RAG-GFP with B-KO splenic Tregs significantly more than 
NOD-RAG-GFP (Fig.1.13B). However, a significant decrease in absolute number 
of B-KO splenic Tregs was observed compared to the FVB-RAG-GFP mice and 
there was no significant difference with the NOD-RAG-GFP mice (Fig.1.13C). 
Ki67 expression showed an increase in the frequency of splenic Ki67+ Tregs of B-
KO mice in comparison to FVB-RAG-GFP (Fig.1.13D). In contrast, Figure 1.13E 
showed no significant difference in absolute number of splenic Ki67+ Tregs 
among the strains which contrasts with the decrease in total splenocyte number 
(Fig.1.13A). 
 
3.4.3 No detectable differences in Tregs residing in pancreatic lymph nodes 
of old NOD mice in comparison to FVB mice total PLN cell numbers 
 
Although there was no significant difference in total PLN cell number among the 
strains, there seems to be a trend of decreased B-KO and NOD-RAG-GFP total 
PLN number that is not significant due to the spread in PLN cell numbers in FVB 
mice (Fig.1.14A). A significant decrease in frequency of B-KO PLN Tregs 
compared to both FVB-RAG-GFP and NOD-RAG-GFP mice was noted 
(Fig.1.14B). Similarly, there was a significant decrease in the absolute number of 
B-KO PLN Tregs compared to FVB-RAG-GFP mice with no significant difference 
with NOD-RAG-GFP mice (Fig.1.14C). In addition, there was also no significant 
difference in frequency of PLN Ki67+ Tregs among the strains (Fig.1.14D). The 
absolute numbers of PLN Ki67+ Tregs among the strains had a similar trend to 
the total PLN cell numbers (Fig.1.14A), with a significant decrease in the Ki67+ 
Tregs in B-KO mice compared with the FVB-RAG-GFP mice (Fig.1.14E). 
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3.4.4 Treg proliferation status may be disease-stage dependent in B-KO 
mice 
 
As mentioned previously in Section 1.6, T1D in NOD mice develops over a 
defined time course divided in three distinct periods; sensitisation, regulation and 
aggression. Thus far, homeostasis of Treg populations was observed during the 
regulation period, 8-14 weeks of age, a critical point of regulation in the PLNs and 
islets before aggression. The next question was whether Treg alterations 
observed during the regulation period applied in other periods as well. Therefore, 
it was decided to observe the homeostatic proliferation of thymic and peripheral 
Treg populations using RAG-GFP mice at a younger age, 4-6 weeks old, during 
the sensitisation period. A total of 18 female (7 FVB-RAG-GFP, 8 NOD-RAG-
GFP and 3 B-KO) 4-6 weeks of age mice were used for this experiment. Gating 
strategy applied for this experiment was identical to the one using the older mice 
(Fig.1.10A). 
 
3.4.5 B cells may play a role in thymic pTreg proliferation of young NOD 
mice 
 
The total thymocyte number among the strains was similar with no significant 
difference (Fig.1.15A). There was also no significant difference in either the 
frequency or absolute number of mTregs among the strains with an unexpected 
level of variance of the NOD-RAG-GFP mice absolute number that could be 
explained by the fact that the data were pulled together from two experiments 
performed on two different days with an identical protocol (Fig.1.15B and C). ND 
and resident mTregs showed no significant difference in both frequency and 
absolute number among the strains (Fig.1.15D, E, F and G). There was a 
significant increase in frequency of B-KO Ki67+ mTregs compared to FVB-RAG-
GFP and NOD-RAG-GFP mice (Fig.1.15H). However, there was no significant 
difference in the absolute numbers of Ki67+ mTregs among the strains, although 
this could be accounted for by the small number of B-KO mice used (Fig.1.15I). 
Data in figure 1.15 were pooled for different experiments with identical protocol. 
Surprisingly, there was a significant decrease in frequency of NOD-RAG-GFP 
pTregs in comparison to FVB-RAG-GFP and B-KO mice (Fig.1.16A). Although 
there was no significant difference in the absolute numbers of pTregs among the 
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strains, looking at the trend of NOD-RAG-GFP mice there seems to be a slight 
decrease compared to FVB-RAG-GFP mice (Fig.1.16B). A significant decrease in 
frequency of ND pTregs was also observed in NOD-RAG-GFP mice compared to 
the other strains (Fig.1.16C) however, there was no significant difference in the 
absolute number of ND pTregs among the strains (Fig.1.16D). Looking at the 
trend of ND pTregs, there seems to be a subtle decrease in the absolute number 
of NOD-RAG-GFP ND pTregs in comparison to the FVB-RAG-GFP mice 
(Fig.1.16D). Although there was a significant increase in frequency of resident 
pTregs of B-KO mice compared to the other strains, more mice should be used in 
the future in order to validate this observation as the spread was too wide and 
only three B-KO mice were available and used at the time (Fig.1.16E). No 
significant difference in the absolute number of resident pTregs was observed 
among the strains (Fig.1.16F). Surprisingly, the frequency of Ki67+ pTregs of B-
KO mice was significantly increased compared to the other strains (Fig.1.16G). 
There was also a significant difference in the absolute number of Ki67+ pTregs 
between FVB-RAG-GFP and B-KO mice (Fig.1.16H). 
 
3.4.6 Increase of NOD splenic Tregs is not due to proliferation 
abnormalities 
 
The total splenocyte number showed an expected significant decrease in B-KO 
mice compared to the other strains (Fig.1.17A). Looking at the frequency of 
splenic Tregs, there was a significant increase in B-KO mice (Fig.1.17B). In 
contrast to their frequency, the absolute number of B-KO splenic Tregs is 
significantly decreased in comparison to FVB-RAG-GFP and NOD-RAG-GFP 
(Fig.1.17C). No significant difference was observed in splenic Ki67+ Tregs 
(Fig.1.17D). However, there was a significant decrease in the absolute number of 
splenic Ki67+ Tregs of B-KO and NOD-RAG-GFP mice compared to FVB-RAG-
GFP. In addition, the absolute number of splenic Ki67+ Tregs of NOD-RAG-GFP 
mice was significantly increased in comparison to B-KO mice (Fig.1.17E). 
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3.4.7 Treg levels in pancreatic lymph nodes of young NOD mice seem to 
alter after pre-insulitis stage 
 
Similarly to the total PLN number of older mice (Fig.1.14A), there was also no 
significant difference among the strains in younger mice (Fig.1.18A). In addition, 
there was no significant difference in either the frequency or absolute number of 
PLN Tregs between the three strains (Fig.1.18B and C). These finding are in 
contrast to the ones observed in older B-KO mice that seem to have roughly a 
25% proportional deduction in frequency between the older B-KO PLN Tregs and 
the other strains, that is not seen in younger mice (Fig.1.14B). Lastly, Ki67 
expression showed no significant difference in both the frequency and the 
absolute number of Ki67+ PLN Tregs among the strains (Fig.1.18D and E). 
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Figures 
 
 
 
 
 
 
 
Fig.1.1 Gating strategies for measuring the frequency and absolute 
numbers of thymocyte subsets. (A) Representative flow plot of B6 thymocytes 
showing gating strategy; lymphocytes excluding doublets and dead cells, gating 
on CD4SP population (B) Representative flow plots showing the CD25 and GITR 
expression of CD4+CD8- thymocytes, gate shows Total Tregs in B6 and NOD 
mice. 
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Fig.1.2 Total Tregs increase in NOD compared to B6 mice. (A) Frequency of 
GITRhi CD25+ CD4SP cells, from B6 and NOD mice. Frequency shown is 
percentage within CD4SP population. (B) Absolute number of GITRhi CD25+ 
CD4SP thymocytes, from B6 and NOD mice. (C) Absolute number of total 
thymocytes, from B6 and NOD mice (mice age; 8-10 wks old, 5 B6 mice were 
males and 4 NOD mice were females, from a single experiment). Data presented 
as mean and scatter plot; p values were determined using non-parametric Mann-
Whitney U test, *p<0.05, ns= not significant, error bars = standard deviation. 
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Fig.1.3 Gating strategy for measuring the frequency and absolute numbers 
of precursor and mature Tregs. Representative flow plots showing the Foxp3 
and GITR expression gated on CD4SP CD25+ thymocytes showing precursor 
and mature Tregs within the subset. 
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Fig.1.4 Thymic mature Tregs increase in NOD compared to B6 mice. (A) 
Frequency of CD4SP GITRhiCD25+ cells, from B6 and NOD mice. (B) Absolute 
number of CD4SP GITRhiCD25+ cells, from B6 and NOD mice. (C) Frequency of 
CD4SP GITRhiCD25+Foxp3- cells, from B6 and NOD mice. (D) Absolute number 
of CD4SP GITRhiCD25+Foxp3- thymocytes, from B6 and NOD mice. (E) 
Frequency of CD4SP GITRhiCD25+Foxp3+ cells, from B6 and NOD mice. (F) 
Absolute number of GITRhiCD25+Foxp3+CD4SP thymocytes, from B6 and NOD 
mice. (G) Absolute number of total thymocytes, from B6 and NOD mice. (mice 
age; 13 wks old, all female, n= 5 per group from a single experiment) 
Frequencies shown is percentage within CD4SP population. Data presented as 
mean and scatter plot; p values were determined using non-parametric Mann-
Whitney U test, *p<0.05, ns= not significant, error bars = standard deviation. 
  
74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1.5 Gating strategy for measuring the frequency and absolute numbers 
of newly developed and resident total thymocyte Tregs. (A) Representative 
histogram showing the GFP intensity of thymocyte populations; double-negative 
(DN), CD8 and CD4 single positive (CD8 SP, CD4 SP) and double-positive (DP), 
from FVB-RAG2p-GFP mice. (B) Representative flow plots showing the GFP 
expression gated on CD4+CD8-GITRhiCD25+ thymocytes, gate shows newly 
developed (GFP+) and resident (GFP-) total Tregs. 
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Fig.1.6 Abnormalities in Treg development of NOD mice. (A) Frequency of 
GITRhiCD25+CD4SP cells within CD4SP thymocytes population, from FVB-RAG-
GFP and NOD-RAG-GFP mice. (B) Absolute number of GITRhiCD25+CD4SP 
thymocytes, from FVB-RAG-GFP and NOD-RAG-GFP mice. Frequency of 
GITRhiCD25+GFP+CD4SP (C) and GITRhiCD25+GFP-CD4SP (E) cells within 
CD4SP thymocytes population, from FVB-RAG-GFP and NOD-RAG-GFP mice. 
Absolute number of GITRhiCD25+ GFP+CD4SP (D) and GITRhiCD25+GFP-
CD4SP (F) thymocytes, from FVB-RAG-GFP and NOD-RAG-GFP mice. (G) 
Absolute number of total thymocytes, from FVB-RAG-GFP and NOD-RAG-GFP 
mice. (mice age; 13-14 wks old, all female, n= 3-6 per group from a single 
experiment) Data presented as mean and scatter plot; p values were determined 
using non-parametric Mann-Whitney U test, *p<0.05, ns= not significant, error 
bars = standard deviation. 
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Fig.1.7 Gating strategy for measuring the frequency and absolute number 
of GFP expression in secondary lymphoid organs. Representative flow plots 
of FVB-RAG-GFP mice gated on CD4+CD8-GITRhiCD25+ population showing the 
GFP expression, gate shows recent thymic emigrants (RTEs) (GFP+) and 
resident (GFP-) total Tregs in the spleen, pancreatic lymph nodes (PLN) and 
inguinal lymph nodes (ILN).  
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Fig.1.8 Diverse alterations of Treg numbers depending on the tissue 
environment. Frequency within CD4SP population (A) and absolute number (B) 
of GITRhiCD25+CD4SP cells of FVB-RAG-GFP, NODuMTKO-RAG-GFP (B-KO) 
and NOD-RAG-GFP; spleen, thymus, ILNs and PLNs. Frequency within CD4SP 
population (C) and absolute number (D) of GITRhiCD25+GFP+CD4SP cells of 
FVB-RAG-GFP, NODuMTKO-RAG-GFP (B-KO) and NOD-RAG-GFP; spleen, 
thymus, ILNs and PLNs.  Frequency within CD4SP population (E) and absolute 
number (F) of GITRhiCD25+GFP-CD4SP cells of FVB-RAG-GFP, NODuMTKO-
RAG-GFP (B-KO) and NOD-RAG-GFP; spleen, thymus, ILNs and PLNs. (G) 
Absolute cell number of spleen, thymus, ILNs and PLNs. (mice age; 9-11 wks old, 
all female, n= 4-6 per group pooled from two independent experiments with 
identical protocol). Data presented as mean and scatter plot; p values were 
determined using one-way ANOVA and post hoc Tukey’s test, *p<0.05, **p<0.01, 
***p<0.001, ns= not significant, error bars = standard deviation.  
Fig.1.9 No change in IL-2 levels. IL-2 levels of thymic supernatants measured 
using ELISA with 2pg/mL sensitivity (mice age; 8-11 wks old, all female, n=12 
from a single experiment). Data presented as mean and scatter plot; p values 
were determined using one-way ANOVA and post hoc Tukey’s test, ns= not 
significant, error bars = standard deviation. 
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Fig.1.10 Gating strategy for measuring the frequency and absolute number 
of Tregs expressing Ki67. (A) Representative flow plots showing the Ki67 
expression gated on CD4SPGITRhiCD25+Foxp3+ thymocytes of FVB-RAG-GFP, 
NOD-RAG-GFP and NODuMTKO-RAG-GFP (B-KO) mice. (B) Representative 
flow plot of FVB-RAG-GFP mice showing GFP expression of precursor and 
mature Tregs. 
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Fig.1.11 Trend towards an increase of mature Treg proliferation in the 
thymus of B-KO and NOD mice. (A) Absolute number of total thymocytes, from 
FVB-RAG-GFP, NODuMTKO-RAG-GFP and NOD-RAG-GFP mice. Frequency 
within CD4SP population (B) and absolute number (C) of 
GITRhiCD25+Foxp3+CD4SP thymocytes, from FVB-RAG-GFP, NODuMTKO-
RAG-GFP and NOD-RAG-GFP mice. Frequency within CD4SP population (D) 
and absolute number (E) of GITRhiCD25+Foxp3+GFP+CD4SP thymocytes, from 
FVB-RAG-GFP, NODuMTKO-RAG-GFP and NOD-RAG-GFP mice. Frequency 
within CD4SP population (F) and absolute number (G) of 
GITRhiCD25+Foxp3+GFP-CD4SP thymocytes, from FVB-RAG-GFP, 
NODuMTKO-RAG-GFP and NOD-RAG-GFP mice. Frequency within CD4SP 
population (H) and absolute number (I) of GITRhiCD25+Foxp3+Ki67+CD4SP 
thymocytes, from FVB-RAG-GFP, NODuMTKO-RAG-GFP and NOD-RAG-GFP 
mice. (mice age; 11 wks old, all female, n= 3-4 per group from a single 
experiment). Data presented as mean and scatter plot; p values were determined 
using one-way ANOVA and post hoc Tukey’s test, *p<0.05, ns= not significant, 
error bars = standard deviation.  
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Fig.1.12 Decrease in newly developed precursor Tregs in B-KO and NOD 
mice is not due to proliferation abnormalities. Frequency within CD4SP 
population (A) and absolute number (B) of GITRhiCD25+Foxp3-CD4SP 
thymocytes, from FVB-RAG-GFP, NODuMTKO-RAG-GFP and NOD-RAG-GFP 
mice. Frequency within CD4SP population (C) and absolute number (D) of 
GITRhiCD25+Foxp3-GFP+CD4SP thymocytes, from FVB-RAG-GFP, 
NODuMTKO-RAG-GFP and NOD-RAG-GFP mice. Frequency within CD4SP 
population (E) and absolute number (F) of GITRhiCD25+Foxp3-GFP-CD4SP 
thymocytes, from FVB-RAG-GFP, NODuMTKO-RAG-GFP and NOD-RAG-GFP 
mice. Frequency within CD4SP population (G) and absolute number (H) of 
GITRhiCD25+Foxp3-Ki67+CD4SP thymocytes, from FVB-RAG-GFP, NODuMTKO-
RAG-GFP and NOD-RAG-GFP mice. (mice age; 11 wks old, all female, n= 3-4 
per group from a single experiment (Fig.1.11)). Data presented as mean and 
scatter plot; p values were determined using one-way ANOVA and post hoc 
Tukey’s test, *p<0.05, **p<0.01, ***p<0.001, ns= not significant, error bars = 
standard deviation. 
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Fig.1.13 Abnormal increase of Treg proliferation in the spleen of B-KO 
mouse. (A) Absolute number of total splenocytes, from FVB-RAG-GFP, 
NODuMTKO-RAG-GFP and NOD-RAG-GFP mice. Frequency within CD4SP 
population (B) and absolute number (C) of GITRhiCD25+Foxp3+CD4SP 
splenocytes, from FVB-RAG-GFP, NODuMTKO-RAG-GFP and NOD-RAG-GFP 
mice. Frequency within CD4SP population (D) and absolute number (E) of 
GITRhiCD25+Foxp3+Ki67+CD4SP splenocytes, from FVB-RAG-GFP, 
NODuMTKO-RAG-GFP and NOD-RAG-GFP mice. (mice age; 11 wks old, all 
female, n= 3-4 per group from a single experiment (Fig.1.11). Data presented as 
mean and scatter plot; p values were determined using one-way ANOVA and 
post hoc Tukey’s test, *p<0.05, **p<0.01, ***p<0.001, ns= not significant, error 
bars = standard deviation. 
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Fig.1.14 PLN Treg decrease in B-KO mice not due to proliferation 
abnormalities (A) Absolute number of total PLN cell number, from FVB-RAG-
GFP, NODuMTKO-RAG-GFP and NOD-RAG-GFP mice. Frequency within 
CD4SP population (B) and absolute number (C) of GITRhiCD25+Foxp3+CD4SP 
PLNs, from FVB-RAG-GFP, NODuMTKO-RAG-GFP and NOD-RAG-GFP mice. 
Frequency within CD4SP population (D) and absolute number (E) of 
GITRhiCD25+Foxp3+Ki67+CD4SP thymocytes, from FVB-RAG-GFP, 
NODuMTKO-RAG-GFP and NOD-RAG-GFP mice. (mice age; 11 wks old, all 
female, n= 3-4 per group from a single experiment (Fig.1.11)). Data presented as 
mean and scatter plot; p values were determined using one-way ANOVA and 
post hoc Tukey’s test, *p<0.05, ns= not significant, error bars = standard 
deviation. 
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Fig.1.15 Treg development not compromised in younger mice (A) Absolute 
number of total thymocytes, from FVB-RAG-GFP, NODuMTKO-RAG-GFP and 
NOD-RAG-GFP mice. Frequency within CD4SP population (B) and absolute 
number (C) of GITRhiCD25+Foxp3+CD4SP thymocytes, from FVB-RAG-GFP, 
NODuMTKO-RAG-GFP and NOD-RAG-GFP mice. Frequency within CD4SP 
population (D) and absolute number (E) of GITRhiCD25+Foxp3+GFP+CD4SP 
thymocytes, from FVB-RAG-GFP, NODuMTKO-RAG-GFP and NOD-RAG-GFP 
mice. Frequency within CD4SP population (F) and absolute number (G) of 
GITRhiCD25+Foxp3+GFP-CD4SP thymocytes, from FVB-RAG-GFP, 
NODuMTKO-RAG-GFP and NOD-RAG-GFP mice. Frequency within CD4SP 
population (H) and absolute number (I) of GITRhiCD25+Foxp3+Ki67+CD4SP 
thymocytes, from FVB-RAG-GFP, NODuMTKO-RAG-GFP and NOD-RAG-GFP 
mice. (mice age; 4-6 wks old, all female, n= 3-7 per group from five independent 
experiments with identical protocol). Data presented as mean and scatter plot; p 
values were determined using one-way ANOVA and post hoc Tukey’s test, 
*p<0.05, ns= not significant, error bars = standard deviation.  
 
 
 
 
 
 
I
 
H
 
89 
 
 
%
 G
IT
R
h
i
C
D
2
5
+
 F
o
x
p
3
-
C
D
4
S
P
 w
it
h
in
 C
D
4
S
P
FV
B
B
-K
O
N
O
D
0.0
0.2
0.4
0.6
0.8
1.0
*
*
G
IT
R
h
i
C
D
2
5
+
 F
o
x
p
3
-
C
D
4
S
P
 t
h
y
m
o
c
y
te
 n
u
m
b
e
r
FV
B
B
-K
O
N
O
D
0
50000
100000
150000
ns
 
 
%
 G
IT
R
h
i
C
D
2
5
+
 F
o
x
p
3
-
G
F
P
+
C
D
4
S
P
 w
it
h
in
 C
D
4
S
P
FV
B
B
-K
O
N
O
D
0.0
0.2
0.4
0.6
0.8
*
G
IT
R
h
i
C
D
2
5
+
 F
o
x
p
3
-
G
F
P
+
C
D
4
S
P
 t
h
y
m
o
c
y
te
 n
u
m
b
e
r
FV
B
B
-K
O
N
O
D
0
20000
40000
60000
80000
100000
ns
 
 
%
 G
IT
R
h
i
C
D
2
5
+
 F
o
x
p
3
-
G
F
P
-
C
D
4
S
P
 w
it
h
in
 C
D
4
S
P
FV
B
B
-K
O
N
O
D
0.00
0.05
0.10
0.15
0.20
0.25 * **
G
IT
R
h
i
C
D
2
5
+
 F
o
x
p
3
-
G
F
P
-
C
D
4
S
P
 t
h
y
m
o
c
y
te
 n
u
m
b
e
r
FV
B
B
-K
O
N
O
D
0
10000
20000
30000
40000
ns
 
 
%
 K
i6
7
+
o
f 
G
IT
R
h
i
C
D
2
5
+
 F
o
x
p
3
-
C
D
4
S
P
 w
it
h
in
 C
D
4
S
P
FV
B
B
-K
O
N
O
D
0.0
0.1
0.2
0.3
0.4
*** ***
K
i6
7
+
o
f 
G
IT
R
h
i
C
D
2
5
+
 F
o
x
p
3
-
C
D
4
S
P
 t
h
y
m
o
c
y
te
 n
u
m
b
e
r
FV
B
B
-K
O
N
O
D
0
10000
20000
30000
40000
50000
*
 
 
 
 
 
 
A
 
B
 
C
 
D
 
E
 
F
 
G
 
H
 
90 
 
Fig.1.16 Increase in precursor Treg proliferation of younger B-KO mice. 
Frequency within CD4SP population (A) and absolute number (B) of 
GITRhiCD25+Foxp3-CD4SP thymocytes, from FVB-RAG-GFP, NODuMTKO-
RAG-GFP and NOD-RAG-GFP mice. Frequency within CD4SP population (C) 
and absolute number (D) of GITRhiCD25+Foxp3-GFP+CD4SP thymocytes, from 
FVB-RAG-GFP, NODuMTKO-RAG-GFP and NOD-RAG-GFP mice. Frequency 
within CD4SP population (E) and absolute number (F) of GITRhiCD25+Foxp3-
GFP-CD4SP thymocytes, from FVB-RAG-GFP, NODuMTKO-RAG-GFP and 
NOD-RAG-GFP mice. Frequency within CD4SP population (G) and absolute 
number (H) of GITRhiCD25+Foxp3-Ki67+CD4SP thymocytes, from FVB-RAG-
GFP, NODuMTKO-RAG-GFP and NOD-RAG-GFP mice. (mice age; 4-6 wks old, 
all female, n= 3-7 per group from five independent experiments with identical 
protocol (Fig.1.15)). Data presented as mean and scatter plot; p values were 
determined using one-way ANOVA and post hoc Tukey’s test, *p<0.05, **p<0.01, 
***p<0.001, ns= not significant, error bars = standard deviation. 
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Fig.1.17 Normal splenic Treg proliferation of younger B-KO mice. (A) 
Absolute number of total splenocytes, from FVB-RAG-GFP, NODuMTKO-RAG-
GFP and NOD-RAG-GFP mice. Frequency within CD4SP population (B) and 
absolute number (C) of GITRhiCD25+Foxp3+CD4SP splenocytes, from FVB-RAG-
GFP, NODuMTKO-RAG-GFP and NOD-RAG-GFP mice. Frequency within 
CD4SP population (D) and absolute number (E) of 
GITRhiCD25+Foxp3+Ki67+CD4SP splenocytes, from FVB-RAG-GFP, 
NODuMTKO-RAG-GFP and NOD-RAG-GFP mice. (mice age; 4-6 wks old, all 
female, n= 3-7 per group from a single experiment (Fig.1.15). Data presented as 
mean and scatter plot; p values were determined using one-way ANOVA and 
post hoc Tukey’s test, *p<0.05, **p<0.01, ***p<0.001, ns= not significant, error 
bars = standard deviation. 
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Fig.1.18 No Treg alterations of PLNs in younger mice (A) Absolute number of 
total PLN cell number, from FVB-RAG-GFP, NODuMTKO-RAG-GFP and NOD-
RAG-GFP mice. Frequency within CD4SP population (B) and absolute number 
(C) of GITRhiCD25+Foxp3+CD4SP PLNs, from FVB-RAG-GFP, NODuMTKO-
RAG-GFP and NOD-RAG-GFP mice. Frequency within CD4SP population (D) 
and absolute number (E) of GITRhiCD25+Foxp3+Ki67+CD4SP thymocytes, from 
FVB-RAG-GFP, NODuMTKO-RAG-GFP and NOD-RAG-GFP mice. (mice age; 4-
6 wks old, all female, n= 3-7 per group from a single experiment (Fig.1.15)). Data 
presented as mean and scatter plot; p values were determined using one-way 
ANOVA and post hoc Tukey’s test, ns= not significant, error bars = standard 
deviation. 
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Discussion 
Type 1 Diabetes (T1D) involves the failure of central tolerance in which 
autoreactive lymphocytes developing in the thymus somehow skip the elimination 
process, resulting in peripheral autoreactive T cells that escaped the thymus. It is 
an autoimmune disorder in which the insulin-producing β cells in the pancreas 
are destroyed by autoreactive T cells resulting in hyperglycaemia leading to short 
and long-term health conditions. Intriguingly, there is a great debate whether the 
paucity and/or defectiveness of Treg cells contribute or perpetuate the β cell 
destruction. Therefore, due to this contradictory body of findings regarding Treg 
numbers using diabetes-prone models, it is important to establish a pattern of 
Treg populations for a better understanding, as they seem to be a necessity in 
preventing autoimmune diseases such as T1D. This project aimed to revisit and 
investigate the development and particularly the homeostatic proliferation of 
Tregs in the thymus and the homeostatic proliferation in peripheral lymphoid 
organs using for the first time RAG-GFP expressing NOD and NOD μMTKO (B-
KO) mice. Our investigations sought to observe Tregs in pre-diabetic NOD mice 
at 2 distinct periods of the disease progression; during ‘Regulation’ 8-14 weeks of 
age (old) and ‘Sensitisation’ 3-6 weeks of age (young). Initially using older mice, 
results showed an overall increase in thymic Tregs elucidated by an increase in 
both precursor and mature Tregs (hereafter called pTregs and mTregs, 
respectively) in comparison to B6 mice, signifying a developmental change in 
thymic Treg population. In addition, flow cytometric analysis also revealed a 
decrease in newly developed (ND) Tregs and an increase in resident Tregs 
identified as GFP+ and GFP- respectively, in comparison to FVB-RAG-GFP mice. 
Interleukin-2 (IL-2) did not seem to be responsible for these alterations as there 
was no difference among the strains. However, based on Ki67 expression to 
assess Treg proliferation, intriguingly NOD thymic mTregs displayed a non-
significant trend towards increase in proliferative status in comparison to FVB-
RAG-GFP mice. Furthermore, we emphasize the importance of observing both 
the frequency and absolute number of Tregs as frequency is only reflective of 
other populations whereas absolute numbers are definitive. Moreover, we 
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speculate that B cells may affect homeostatic proliferation of Tregs in an age-
dependent manner. In regards to peripheral Tregs residing in the spleen and 
pancreatic lymph nodes (PLNs), we observed a significant increase in frequency 
that was not however observed in the absolute numbers, of splenic Tregs and no 
alteration in PLN Tregs of NOD-RAG-GFP mice in comparison to FVB-RAG-GFP 
mice was documented despite age. 
 
4.1 Homeostatic proliferation alterations in thymic Treg 
populations of NOD mice 
 
4.1.1 Increase in thymic Treg numbers of NOD mice in comparison to B6 
 
Tregs have been established to play an essential role in the maintenance of self-
tolerance by controlling self-reactive T cells (Sakaguchi 2004). In regards to 
thymic Treg proportions using diabetes-prone mouse models, there have been 
controversial findings trying to establish in part the reasons of lack of peripheral 
tolerance leading to pancreatic β cell destruction in T1D. In our investigation 
using older NOD mice in comparison to slightly younger B6 mice as a control that 
were available at the time, we documented a trend towards increase in frequency 
and a significant increase in the absolute number of thymic Tregs (Fig.1.2A and 
B). Ideally the age of the mice should be the same, nonetheless both strains were 
still considered to be in the same phase of diabetes development that 
compromised for the slight age difference. Complementing our results, Feuerer 
M. et al. demonstrated in vitro using fetal thymus organ cultures of NOD mice, 
their capability of generating Tregs without defects in their thymic selection 
process in comparison to B6.H-2g7 mice, a NOD MHC class II-matched diabetes 
resistant mouse model (Feuerer et al. 2007). In addition, in agreement with our 
findings (Fig.1.2) more recently a relatively elevated frequency and absolute 
number of Tregs in NOD thymi was also displayed by Tellier J. et al. with a 
similar approach to ours using flow cytometry to analyze the co-expression of 
CD4, CD25 and Foxp3 of B6 and NOD mice (Tellier et al. 2013). However, Tellier 
J. et al. argues that it is very unlikely that this quantitative increase of Tregs in 
NOD mice is associated with their susceptibility to diabetes as both their control 
B6 mice and NOD mice developed diabetes with the same kinetics (Tellier et al. 
2013). Furthermore, Zhen Y. et al. and colleagues used streptozotocin (STZ)-
95 
 
induced diabetic mice to study the effects of long-term hyperglycemia on 
CD4+CD25+ Tregs in vivo (Zhen et al. 2011). STZ is a naturally occurring 
chemical that is toxic to beta cells and is used to produce animal models for T1D. 
Part of their results showed a significant increase in the frequencies of CD25+ 
and Foxp3+ nTregs in the thymi of mice with diabetes among all CD4 single 
positive (CD4SP) cells at 1 up to 4 months from the onset of diabetes (Zhen et al. 
2011). Our results complement their findings as we also observed an increase in 
thymic Treg frequency at the pre-diabetic stage (Fig.1.4.). This gives rise to the 
question whether thymic Tregs in diabetes-prone mice remain enhanced in 
frequency throughout the disease progression or whether there is a certain time 
point where thymic Treg numbers are enhanced in diabetes-prone mice. 
Altogether, these studies supported our initial in vivo finding of increased thymic 
Treg populations, documenting an overall increase in thymic Tregs in NOD mice 
at the pre-diabetic stage in comparison to B6 mice (Fig.1.2 and 1.4). On the other 
hand, others have shown a significant decrease in thymic Tregs in NOD mice 
defined as CD4+CD25+ via flow cytometric analysis in comparison to BABL/c 
mice as a control, which could potentially explain their inability to maintain 
peripheral tolerance according to them (Wu et al. 2002). However, this decrease 
of thymic Tregs in NOD mice at 3 weeks of age may be accounted by the 
reduced thymus size in comparison to the control that resulted in a reduction of 
all thymocyte populations and not just Tregs (Wu et al. 2002). Additionally, an 
important question to ask is whether the control mice strains used in various 
studies including ours, represent realistic clinical findings that could be translated 
in patients later on as there are variations between control mouse strains. In 
contrast to both concepts of thymic Tregs either increasing or decreasing in 
diabetes-prone mice in comparison to controls, D'Alise A.M. et al. supports the 
notion of no deficit of thymic Treg frequencies in NOD mice where Tregs were 
identified based on CD4 and Foxp3 co-expression (D'Alise et al. 2008). It is 
possible that the use of different diabetes-prone mice models and controls in 
combination with different approaches, in vitro or in vivo investigations, as well as 
detection of Tregs using different marker panels, could explain the controversy of 
the findings between the studies mentioned above. Nonetheless, our findings in 
agreement with others stated above, support the notion of an increase in thymic 
Tregs in old NOD mice compared to B6 mice (Fig.1.2 and 1.4). Previously, it was 
demonstrated that in the absence of TGF-β receptor on T cells specifically, 
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resulted in the majority of T cells spontaneously differentiating in type 1 and type 
2 cytokine secreting cells (Gorelik and Flavell et al. 2000). Additionally, it is 
known that T cell differentiation is highly regulated in part by the cytokine 
environment available at the time of antigen recognition (Murphy and Reiner et al. 
2002, Zhu et al. 2009). For instance, Dang EV. et al. demonstrated a balance 
between Treg and Th cell 17 differentiation, regulated by a key metabolic sensor, 
hypoxia-inducible factor 1 (Dang et al. 2011). Therefore, it is possible that T cells 
may have differentiated at an abnormal rate in NOD mice towards Treg lineage 
due to impaired signalling pathways or antigen presentation (Bousso and 
Deguine 2011, Brincks et al. 2013). Although this increase could not distinguish 
between pTregs and mTregs due to lack of forkhead box P3 (Foxp3) marker 
(Hori 2003), another potential reason that could explain this result is possibly the 
retention and/or accumulation of re-circulated peripheral Tregs back to the 
thymus (McCaughtry et al. 2007). In addition, our documented increase (Fig.1.2 
and 1.4) could also be accounted by an uncontrollable Treg expansion in the 
thymus by a mechanism similar to Tregs limiting activated T cell expansion 
(Bosco et al. 2006). However, these observations are paradoxical as Tregs are 
established to play key roles in the maintenance of immunologic self-tolerance 
(Sakaguchi et al. 2006) and therefore one would expect inhibition of T1D 
progress with enhanced Treg populations. However, it has been previously 
suggested that Tregs have reduced ability to suppress autoreactive T cells cells 
in β cells with age, that could explain this oddity (Gregori et al. 2003, You et al. 
2005).  
 
4.1.2 Increase in thymic Tregs due to an increase in both precursor and 
mature Tregs signify a developmental fault 
 
Foxp3 intracellular transcription factor has been shown to be essential for Treg 
development and functionality (Fontenot et al. 2003, Hori 2003, Khattri et al. 
2003). Therefore, Foxp3 represents a more specific marker for Treg identification 
in contrast to previous vastly used markers such as CD25, CD45RBlo, CTLA-4, 
CD62L, CD103 and GITR (Fehérvari and Sakaguchi 2004). Hence the use of 
Foxp3 in experiments in order to differentiate between Treg subpopulations such 
as pTregs and mTregs (Lio and Hsieh 2008, Burchill et al. 2008), as well as from 
activated, effector and memory T cells (Hori 2003, Zhan et al. 2007), is crucial for 
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a more precise analysis of Treg development and homeostasis. Tracking the co-
expression of CD4, CD25, GITR and Foxp3 simultaneously, allowed distinction of 
pTregs from mTregs as previously described (Lio and Hsieh 2008, Burchill et al. 
2008). Many studies predominantly identified Tregs with the individual co-
expression of either CD25, GITR, CTLA-4 and/or Foxp3 on CD4SP cells, 
neglecting a separate analysis of pTregs from mTregs in the thymus, in order to 
investigate either the proportions or functionality of Tregs (Gregori et al. 2003). 
To our knowledge, no previous study has directly addressed homeostatic 
changes in thymic Tregs between pTregs and mTregs in NOD mice at the pre-
diabetic stage. Interestingly, it appeared that there was a trend towards increase 
in pTregs and a significant increase in mTregs of older NOD mice compared to 
B6 control mice (Fig.1.4) (which could potentially account for the documented 
increase in total Tregs (pTregs and mTregs) in our findings (Fig.1.2 and 1.4) and 
others (Tellier et al. 2013). Therefore, based on these results without verifying 
evidence from others, we speculate that these alterations may have been due to 
developmental abnormalities at earlier stages of Treg development, resulting in 
more pTregs and subsequently more mTregs. Interestingly, preliminary data 
observing GITR expression at the double negative (DN) stages of thymocyte 
development, showed an elevated expression of GITR at the DN3 and DN4 
stages of development in NOD mice in comparison to B6 (data not shown). 
Previous study demonstrated a critical role of GITR in dominant immunological 
self-tolerance maintained by CD4+CD25+ Tregs as signalling through GITR could 
override Treg-mediated suppression (Shimizu et al. 2002). Alteration of surface 
molecules in DN stages was not explored in depth in our investigation. However, 
it is possible that the increase in NOD pTregs could be a result of higher or lower 
expression of certain crucial cell surface molecules for development and/or 
functionality. Another plausible reason which could explain these results is a 
higher proliferation status of pTregs, that is disputed by further on findings.  
 
4.1.3 Decrease in newly developed Tregs of NOD-RAG-GFP reporter mice 
indicates possible compromise in Treg development 
 
Back in 1999, RJ. Monroe et al. and colleagues created a novel reporter mouse 
in which the endogenous RAG2 coding exon was replaced by a RAG2:GFP 
fusion gene in order to investigate further the developmental stages and 
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physiological factors that lead to modulation of RAG expression  (Monroe et al. 
1999). Alternatively, others constructed bacterial artificial chromosomes (BACs) 
modified by homologous recombination to encode GFP as a reporter instead of 
RAG2. BACs were then carried by transgenic mice in order to examine the 
regulation of RAG expression (Yu et al. 1999). In regards to Tregs, groups using 
RAG-GFP reporter mice have investigated Treg production by tracking thymic 
output of Tregs searching for recent thymic emigrants (RTEs) in the periphery 
based on GFP expression (Chougnet et al. 2010). In addition, our lab previously 
examined whether the CD40-CD154 pathway played a role in the thymic 
development of Tregs while looking at thymic resident and ND Tregs defined as 
GFP- and GFP+ respectively (Cuss and Green 2012). Alternatively, 
bromodeoxyuridine (BrdU) was used to detect RTEs after 2 days of continuous 
administration (Tough 1994, McCaughtry et al. 2007). BrdU is a synthetic 
analogue of thymidine nucleoside and acts as a marker of DNA synthesis as it is 
incorporated in cells undergoing DNA replication which ultimately allows 
identificiation of actively dividing cells (Lin and Riggs et al. 1972, Duque and 
Rakik et al. 2011). Therefore, RTEs which have a higher proliferation status as 
they have just migrated from the thymus to the periphery, can be distinguished 
from other cells (McCaughtry et al. 2007). In our investigation using for the first 
time NOD-RAG-GFP mice in comparison to FVB-RAG-GFP mice, we 
documented a significant decrease in both the frequency and absolute number of 
ND Tregs of NOD mice (Fig.1.6C and D) in contrast to a significant increase in 
frequency and a non-significant trend towards increase in absolute number of 
resident thymic Tregs (Fig.1.6E and F). The decrease observed in ND Tregs is 
most unlikely to be accounted by a faster transition to the resident phenotypic 
characterisation, as GFP intensity declines at a constant rate with a half-life ~56 
h in vivo as previously shown (McCaughtry et al. 2007). Despite the fact that 
there was no significant difference in total Tregs between FVB-RAG-GFP and 
NOD-RAG-GFP mice (Fig.1.6A and B) as previously shown in B6 and NOD mice 
(Fig.1.2A and B), NOD-RAG-GFP mice seem to have a constant Treg frequency 
irrespective of RAG-GFP expression. One major cause for non-significance in our 
results is the small group size used. However, our pilot experiments now allow us 
to calculate a level of variance within experimental groups, therefore future 
experiments can be adequately powered to detect significant changes. Others 
have previously documented a similar concern where gene-targeted mice in the 
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B6 background frequently bred into the polyomavirus middle T mouse model of 
breast cancer in the FVB strain, showed altered phenotypes (Davie et al. 2007). It 
is therefore essential to use animal models that would recapitulate clinical 
findings however, FVB mice were the only strain available harbouring RAG-GFP 
expression to be used as a comparison at the time. In addition, this non-
significance could also be accounted by an insufficient number of mice used in 
order to detect statistical significance. Furthermore, there was a significant 
increase in the frequency and a non-significant trend towards increase in 
absolute number of resident Tregs. In agreement with others, a significant 
proportion of thymic Tregs is comprised of thymic resident Tregs (McCaughtry et 
al. 2007). Some studies suggested  that these resident thymic Tregs may 
originate from peripheral Tregs re-circulating back to the thymus, as 
demonstrated in GK mice that lack generation of peripheral CD4 T cells due to 
the transgenic expression of anti-CD4 monoclonal antibodies that depletes 
peripheral CD4 T cells (Zhan et al. 2007) or using lymphopenic mice (Bosco et al. 
2006). Another explanation is a possible retention or increased thymic Treg cell 
division (McCaughtry et al. 2007).  Although these results cannot distinguish 
between pTregs and mTregs, the decrease of ND Tregs still signifies an 
abnormality in Treg development. Therefore, it is of great importance for 
subsequent investigations to include separate analysis of these two Treg 
subpopulations for a more precise and insightful picture on Treg development 
and homeostasis in NOD mice as they have unique homeostatic properties. 
Concluding, based on our findings we speculate that due to a defect in Treg 
development occurring either at a certain point or throughout the pre-diabetic 
stage of NOD mice that may or may not be true at the diabetic stage, could result 
in the malfunction of Tregs in an age-dependent manner as previously suggested 
leading to β cell destruction. (Gregori et al. 2003, You et al. 2005). 
 
4.1.4 B cells may be involved in thymic Treg development and/or 
homeostasis in a disease progression stage-dependent manner 
 
B cells are a distinct lymphocyte population that was initially discovered by Emil 
von Behring and Shibasaburo Kitasato in 1890 (Behring et al 1890). Since then 
extensive investigations on B cells elucidated their crucial role in humoral 
antibody-mediated immunity (Cooper 2015). Concurrently, further studies 
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indicated the ability of B cells to act as professional APCs able to generate or 
regulate in part immune responses by activating or tolerizing T cells in a variety of 
autoimmune diseases such as systemic 
 lupus erithematosus (Mamula et al. 1994, Chan et al. 1999), rheumatoid arthritis 
(Takemura et al. 2001), T1D (Falcone et al. 1998, Greeley et al. 2001, Silveira et 
al. 2002, Wong et al. 2004) and multiple sclerosis (Lyons et al. 1999). In regards 
to T1D,  B cells similarly to T cells seemed to infiltrate pancreatic islets of NOD 
mice and in combination with the presence of autoantibodies against the islet 
antigens in these mice, lead to the hypothesis that B cells are vital in the disease 
progression (Signore et al. 1989). Subsequently, indeed it was demonstrated by 
DV. Serreze et al. that B cells were essential in the initiation of T cell-mediated 
autoimmune diabetes using NOD.Igμnull mice that lacked functional B 
lymphocytes (Serreze 1996). Similarly, others have shown protection of B cell-
deficient or or anti-μ Ab-treated NOD mice from diabetes (Forsgren et al. 1991, 
Yang et al. 1997, Noorchashm et al. 1997). On the other hand, in contrast to the 
notion of mature B cells being essential in the pathogenesis of diabetes in NOD 
mice, M. Yang et al. suggested that this was not the case at least in some mice 
according to their findings (Yang et al. 1997). However, recently our group has 
documented that the NOD thymus is abnormal by having a significant increase in 
thymic B cells as mice progress to diabetes. These thymic B cells secrete 
autoantibodies that target insulin expressing thymic stroma cells inducing their 
apoptosis and as a consequence may impair negative selection of autoreactive T 
cells (Pinto et al, submitted). Nonetheless, the influence these thymic B cells 
have on Treg development is unknown. Intriguingly, more recently FT. Lu et al. 
and colleagues suggested a role of thymic B cells in regulating the number of 
thymic Treg cell population using B6 mice (Lu et al. 2015). To our knowledge, in 
regards to thymic Treg development and B cells in diabetes-prone mice have not 
yet been investigated. Therefore, in addition to NOD-RAG-GFP mice, using B cell 
deficient NOD mice expressing RAG-GFP (B-KO), we sought to observe any 
correlation between B cells and the development/homeostasis of thymic Tregs 
and their subpopulations initially at the pre-diabetic stage while looking at Ki67 
expression, a nuclear protein commonly used as a marker for cellular division 
(Scholzen and Gerdes 2000, Akimova et al. 2011). The commonality that brings 
NOD-RAG-GFP and B-KO mouse strains together is their NOD genetic 
background thus, any changes observed between them imply a direct or indirect 
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impact by B cells. In our investigations we observed a non-significant increase in 
the of proliferative status of thymic mTregs (Fig.1.11A) but not of pTregs of old 
NOD-RAG-GFP and B-KO mice (Fig.1.12G) compared to FVB-RAG-GFP mice. 
This raises the question whether these highly proliferative Tregs emigrated from 
the thymus to the periphery as previously suggested (McCaughtry et al. 2007), 
due to the ongoing infiltration of pancreatic β cells at that stage or whether these 
Tregs have a lower survival rate. Furthermore, the similarity of Treg patterns 
between older NOD-RAG-GFP and B-KO mice (Fig.1.11 and 1.12) implied no 
effect of B cells on Tregs at the regulation stage of disease progression (see 
section 1.6.1). It is also worth noting that in contrast to our previous findings 
indicating a non-significant trend towards increase of pTregs in NOD mice 
compared to B6 (Fig.1.4B and C), both B-KO and NOD-RAG-GFP mice showed 
a significant decrease in both frequency and absolute number of pTregs in 
comparison to FVB-RAG-GFP mice (Fig.1.12A and B). However, their frequency 
is constant throughout the experiments in contrast to FVB-RAG-GFP mice, and 
the decrease in their number could be accounted due to following a slightly 
different protocol for the experimental groups in Figure 1.12 that consisted more 
washes compared to the protocol followed for the experimental groups in Figure 
1.4, therefore losing more cells by the end of the process. This decrease could 
also be accounted by the overall decrease in thymocyte number (Fig.1.11I). FT. 
Lu et al., documented  a significant decrease in frequency and number of thymic 
Tregs of μMT FoxP3-GFP mice that lacked functional B cells compared to 
FoxP3-GFP mice as their control (Lu et al. 2015). However, in our results despite 
the fact that NOD-RAG-GFP mice have functional B cells, their mTreg frequency 
and number is similar to B-KO mice (Fig.1.11C and D) therefore opposing the 
concept of B cells’ effect on thymic Tregs that FT. Lu et al. suggested which is 
the contribution of B cells in thymic Treg maintenance. This contradiction could 
possibly be explained by the use of different mouse models with a significantly 
different health background; healthy versus pre-diabetic mice. Sequentially, in 
order to observe whether these alterations differed in any way in other stages of 
the disease (see section 1.6.1), we chose to observe the sensitisation stage in 
younger mice due to time constrictions and mice available at the time. We 
documented similar frequency of pTregs between B-KO and FVB-RAG-GFP 
young mice but not in NOD-RAG-GFP mice that had a significantly lower 
frequency in comparison to the other strains and a non-significant trend towards 
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decrease in their absolute number compared to the control (Fig.1.16A and B). 
Moreover, in contrast to older mice Treg proliferative status that showed no 
significant difference among the strains (Fig.1.11 and 1.12), in younger mice we 
observed significant increase in frequency and a non-significant trend towards 
increase in absolute number of mTreg Ki67 exression of B-KO mice in 
comparison to the other strains (Fig.1.15H and I) and similarly a significant 
increase in pTreg Ki67 expression of B-KO mice in comparison to the other 
strains, however these experiments should be repeated with more mice in order 
to be verified as only three B-KO mice were available at the time (Fig.1.16G and 
H). Therefore, we agree with the concept proposed by FT. Lu et al. of a non-
redundant role of thymic B cells regulating the number of thymic Treg cell 
population, yet  our results differ from their findings of a suggested decrease in 
Treg proportions of B cell deficient mice (Lu et al. 2015). However, due to the 
small number of mice used for our experiments, statistical significance in some 
cases (i.e. proliferative mTregs in young and old mice) was not conferred 
therefore, speculations mentioned in this section could be disputed or verified in 
future investigations. Furthermore, we want to emphasize the importance of 
analysing and observing both the frequency and number of Treg populations, as 
we documented significant differences in both GFP+ and GFP- pTreg frequencies 
of young mice among the strains that was not supported by their absolute 
numbers (Fig.1.16C, D, E and F). Numerous studies have formed their 
conclusions based solely on either frequencies or absolute number patterns that 
may not necessarily be the same when obtained together as we observed. 
Therefore, future experiments looking at both frequencies and absolute number 
would provide more evident results. Nonetheless, overall based on our results we 
hypothesize an involvement of B cells in thymic Treg development and/or 
homeostatic proliferation depending on the stage of disease progression the mice 
are. 
 
4.1.5 Thymic Treg alterations not due to changes in interleukin-2 levels 
 
Another reason that could elucidate these thymic Treg alterations in NOD mice 
besides B cells and proliferation status, is their maintenance in the thymic 
microenvironment. Interleukin-2 receptor alpha chain (CD25) was discovered to 
be a constitutively expressed Treg marker that allowed distinction of Tregs from 
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other inactive T cell populations, but not from activated T cells as they express it 
as well (Gregori et al. 2003, Fontenot et al. 2005, Paschou 2011) in normal naive 
animals. Based on this discovery several studies later on uncovered an essential 
role of interleukin-2 (IL-2) in Treg function both in vivo and in vitro (Furtado et al. 
2002, de la Rosa et al. 2004). IL-2 is a pleiotropic cytokine historically initially 
described as a T cell growth factor, subsequently demonstrated to promote Treg 
survival and function as well as controlling Treg development and homeostasis 
(Antony et al. 2006, Burchill et al. 2008, Grinberg-Bleyer et al. 2010, Sakaguchi 
2011). For instance, IL-2 or CD25 deficient mice all developed autoimmune 
diseases with age as they had little or no Tregs in their periphery verifying their 
importance to Tregs survival, maintenance and/or development (Malek et al. 
2002, Almeida et al. 2002). In addition, IL-2 levels were suggested to be closely 
linked to Treg homeostasis as a feedback mechanism in order to control T cell 
expansion during immune responses (Almeida et al. 2006). Furthermore, IL-2 
was demonstrated to reverse temporarily established T1D in NOD mice via low 
dose of IL-2 injection (Grinberg-Bleyer et al. 2010). However, high doses of 
exogenous administration of IL-2 in vitro seemed to abrogate the suppressive 
activity of Tregs (Moon et al. 2015) which illustrates the complex immunological 
pathways in feedback mechanisms. On the other hand, it was previously 
suggested that in BB rats that spontaneously develop T1D similarly to NOD mice, 
IL-2 administration enhanced spontaneous development of T1D (Kolb et al. 1986) 
contradicting other findings. Therefore, we assessed if thymic IL-2 levels in FVB-
RAG-GFP, NOD-RAG-GFP and B-KO mice could explain the thymic Treg 
alterations observed at the pre-diabetic stage. J. Yamanouchi et al. and 
colleagues aimed to test effects of the NOD allele of insulin-dependent-diabetes 
3 (Idd3) encoding the IL-2 gene. They demonstrated ~50% decrease in IL-2 
production by CD8+ T cells in non-transgenic NOD mice (Yamanouchi et al. 
2007). Although we did not assess IL-2 production by thymocytes and only 
observed the total IL-2 levels tracked using enzyme-linked immunosorbent assay 
(ELISA), present in thymi of each strain, our results in contrast to the notion of an 
IL-2 decrease in NOD mice, showed no significant alterations in thymic IL-2 
levels among the strains. It is worth noting that these IL-2 levels account for both 
IL-2 present intracellularly and extracellularly of total thymic cells, therefore 
differences between IL-2 available in the extracellular matrix and IL-2 within 
thymocytes cannot be distinguished. Interestingly, although A. Antov et al. using 
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IL-2 deficient mice revealed a vital role of signal transducer and activator of 
transcription 5 (STAT5) transcription factor in CD4+CD25+ Treg homeostasis and 
hence maintenance of self-tolerance, in regards to thymic Treg levels they 
seemed to be similar in either STAT5 or IL-2 deficient mice in comparison to wild 
type, yet they were lacking Foxp3 marker in their experiments (Antov et al. 2003). 
However, most likely their results were skewed as they might have included in 
their results other T lymphocyte populations such as activated effector T cells, as 
previously suggested (Hori 2003, Zhan et al. 2007) due to the fact that they 
lacked Foxp3 marker in their experiments, making their conclusion less reliable. 
Additionally, another group utilizing sequencing assays revealed a mutation in 
Stat5b gene, part of the STAT protein family, situated in chromosome 11 that was 
previously mapped for T1D susceptibility in NOD mice (Davoodi-Semiromi et al. 
2004). Furthermore, later on IL-2 mediated JAK-STAT5 signalling pathway was 
demonstrated to be essential for maintaining Foxp3 expression in thymic Tregs 
(Murawski et al. 2006) and the development of Foxp3+ Tregs (Burchill et al. 
2007). Since we did not observe any alterations in IL-2 levels among the strains 
that could explain our findings (Fig.1.9), one would assume that the JAK/STAT5 
signalling pathway is not impaired. However, our experiments cannot verify this 
assumption and future experiments on JAK/STAT5 pathway in particular would 
elucidate whether this pathway accounts for the alterations observed in thymic 
Tregs in NOD mice. Therefore based on our results, we conclude that the 
alterations of thymic Tregs did not occur due to IL-2 level instabilities implying 
survival, induction and/or expansion were not compromised because of this. 
Nonetheless, as far as we know they could have been compromised by other 
factors not assessed by our investigations such as JAK/STAT5 signalling 
pathway (Murawski et al. 2006) or apoptosis (Shi et al. 1995). In summary, even 
though IL-2 has an essential role in Treg function, development and homeostasis, 
there seems to be no compromise among the thymi of pre-diabetic strains 
although IL-2 levels in other lymphoid organs and periods of the disease are yet 
to be investigated. 
 
Overall, based on our attempts to investigate thymic Treg development and 
homeostasis we conclude that there is a fault in Treg development at earlier 
stages of T1D with B cells being involved as well in pTreg development. Lastly, 
IL-2 and proliferation status defined by Ki67 expression do not seem to account 
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for these thymic Treg alterations. Repetition of these experiments with more mice 
and a more suitable control for comparison would clarify a constant pattern, 
leading to new biological questions thus investigations enhancing our knowledge 
on Tregs in diabetic mice. 
 
4.2 Peripheral Treg populations affected differently 
in NOD and B cell deficient NOD mice in a tissue-
dependent manner 
 
4.2.1 Tregs proliferation status of NOD-RAG-GFP mice show a non-
significant trend in the spleen depending on disease progression 
 
Failing peripheral immunoregulatory mechanisms potentially followed by 
compromised peripheral tolerance, are believed to contribute in T1D progression 
(Rapoport 1993, Salomon et al. 2000, Gregori et al. 2003). Therefore, a vast 
number of research has been conducted on peripheral Treg proportion and/or 
functionality in order to elucidate any abnormalities of peripheral Treg populations 
in diabetes-prone mice. Intriguingly, in regards to peripheral Treg proportion 
(frequencies and/or absolute numbers), there are discrepancies amongst 
findings. Hence we decided to revisit and re-investigate peripheral Treg 
populations using FVB-RAG-GFP, NOD-RAG-GFP and B-KO mice initially in the 
spleen at two distinct stages of T1D disease progression; sensitisation and 
regulation (see section 1.6.1).  
 
The spleen is a secondary lymphoid organ found in most vertebrates and acts 
primarily as a blood filter organ (Steiniger and Barth 2000). In addition to that, the 
spleen has been demonstrated to play an essential role in B cell development as 
immature B cells have been illustrated to migrate from the bone marrow via the 
bloodstream to the spleen, where their development regulated by Notch 
signalling is completed (Kuroda et al. 2003, Mebius and Kraal 2005). Regarding 
our investigations, although the absolute numbers of splenic Tregs in NOD-RAG-
GFP and FVB-RAG-GFP mice were similar in younger mice (Fig.1.17C), we still 
suspect that there was a non significant increase of splenic Tregs in old NOD-
RAG-GFP mice in comparison to the control due to the fact that NOD-RAG-GFP 
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mice were significantly less in total splenocyte number compared to FVB-RAG-
GFP mice (Fig.1.17A) and one would expect that all cell populations (including 
Tregs) within the spleen, would be proportionally less as well. This is also implied 
while looking at the frequency of splenic Tregs of younger mice (Fig.1.17B) 
where there is a non-significant trend towards increase in NOD-RAG-GFP mice 
compared to FVB-RAG-GFP mice. In addition, we did not document any 
significant alterations in splenic Tregs between NOD-RAG-GFP and FVB-RAG-
GFP mice (Fig.1.13). Furthermore, splenic Tregs of old B-KO mice displayed a 
significant increase in proliferation status based on their frequency, but not in 
their absolute numbers, that was not observed in younger mice (Fig.1.13D and 
1.17D). The total splenocyte number in both young and old B-KO mice (Fig.1.13D 
and 1.17D) was plummeted as  B cells are a major portion of the spleen (Berzins 
et al. 2003, Mebius and Kraal 2005). Previously, in disagreement with our 
findings, AJ. Wu et al. suggested a significant decrease in the absolute number of 
splenic CD4+CD8-CD25+ Tregs in NOD mice compared to BALB/c mice at 3, 8 
and 15 weeks of age (Wu et al. 2002). One possible reason that could explain the 
contradictory body of findings is the use of different control mouse models and 
this concept was challenged by SP. Berzins et al. and indeed found significant 
alterations between BALB/c and B6 non-autoimmune control mice of pooled 
lymph nodes (Berzins et al. 2003). Correspondingly to the notion of deficient 
peripheral Tregs in diabetes-prone mice that could be associated with 
autoimmune disease development, P. Alard et al. also demonstrated lower 
frequencies of splenic CD4+CD25+ Tregs of 9 week old NOD mice compared to 
B6 control mice in contrast to our frequencies where we documented a significant 
increase in frequency of splenic Tregs of old NOD mice compared to the control 
that was not however projected by their absolute numbers (Fig.1.13B and C) 
(Alard et al. 2006). Based on our results, it is worth pointing out again the 
importance of inspecting both the frequency and the absolute number of 
populations as they are more definitive than the changes observed in frequencies 
that could well be an artefact of other lymphocyte population changes that have 
not been analyzed in our studies. However, in both investigations (Wu et al. 
2002, Berzins et al. 2003) they lacked Foxp3 marker that is essential for 
distinguishing CD4+CD25+ Tregs from activated T cells (Fontenot et al. 2003) 
amongst other phenotypically similar T lymphocytes (Hori 2003, Zhan et al. 2007) 
that could skew their results. On the other hand, others support the notion of no 
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splenic Treg deficit in NOD mice in comparison to other non-autoimmune prone 
mouse strains at the pre-insulitis stage (Berzins et al. 2003) or throughout the 
different stages of T1D disease progression (Mellanby et al. 2007, D'Alise et al. 
2008), questioning the growing hypothesis that the abnormal functional activity of 
Tregs could be an essential step in the development of T1D. At first glance based 
on absolute numbers (Fig.1.17C) our results on young NOD-RAG-GFP mice 
seem to be in agreement with the concept of no alterations at the prediabetic 
stage (Berzins et al. 2003, Mellanby et al. 2007). In regards to old B-KO mice, we 
documented a significant increase in the frequency of Ki67 expressing splenic 
Tregs that was not seen in their absolute number, in comparison to the other 
groups (Fig.1.13D and E). Similarly to our case, Y. Zhen et al. noted a universal 
decrease in the total splenocyte number, including CD4+ T cells, that projected in 
a significant decrease in CD4+CD25+Foxp3+ splenic Tregs of STZ-induced 
diabetic mice in comparison to their control (Zhen et al. 2011). Therefore, the 
similar numbers of Ki67 expressing splenic Tregs in old B-KO mice among the 
other two strains implies and supports the increase observed in their frequency. 
However, due to the small number of mice and the significant decreased spleen 
cellularity of old B-KO mice compared to the other strains, it is hard to distinguish 
such a change in their splenic Treg numbers although their frequencies 
significantly increased (Fig.1.13D). To our knowledge, there has not been 
extensive research between Treg homeostasis and B cells in the periphery of 
diabetes-prone mice. Nonetheless, our results imply a correlation between the 
homeostatic proliferation of splenic Tregs and B cells in an age-dependent 
manner as there were no alterations in younger mice. Whether this pattern 
persist in diabetic mice or whether these highly proliferative splenic Tregs in B-
KO mice are functional is unknown.  
  
4.2.2 There is no significant trend in Tregs residing in pancreatic lymph 
nodes of NOD mice despite age 
 
The PLNs seem to be a key site for activation and tolerance induction of 
autoreactive T cells against β cells in T1D (Höglund et al. 1999). Hitherto, T1D 
progression was suggested to depend on a delicate balance between Tregs and 
effector Th cells in both the PLNs and the inflamed pancreas (Bluestone and 
Tang 2005). Although we did not investigate the numbers of effector Th cells, 
108 
 
initially we observed a nonsignificant increase in  the absolute number of total 
Tregs of NOD-RAG-GFP mice compared to FVB-RAG-GFP  mice as depicted in 
Figure 1.8, contradicting previous findings suggesting a decrease in PLN Tregs in 
NOD mice (Pop et al. 2005, Nti et al. 2012). Intriguingly, previously chronic 
inflammation has been shown to increase Treg frequencies in the PLNs of T1D-
mouse models prior to diabetes development and these Tregs were hyper-
suppressors of the autoreactive response (Green et al. 2002). However, due to a 
change in our protocol using the same strains as before FVB-RAG-GFP, NOD-
RAG-GFP and B-KO, in order to introduce Ki67 in the markers panel, dissimilarly 
to the spleen there were some alterations in our findings in sequential 
experiments as depicted in Figure 1.14 and 1.18, regarding PLN Tregs probably 
due to their smaller cellularity resulting in more obvious changes. For example, 
looking at the non-significant trends of the experimental groups, in contrast to 
before (Fig.1.8B), there was no difference in PLN Treg number of old NOD-RAG-
GFP mice (Fig.1.14C) compared to the other groups. Furthermore, we 
documented no alterations in PLN Tregs among the strains at the earlier-stages 
of insulitis of younger mice (Fig.1.18). In addition, we also noticed a universal 
decrease in PLN cellularity (Fig.1.14A and 1.18A) possibly due to the extra 
washing steps required for the Ki67 protocol. In disagreement with our findings, 
according to SM. Pop et al. they demonstrated a decline in the frequency of 
Foxp3+CD25+CD62Lhi Treg cells residing in the PLNs of NOD mice in an age-
dependent manner compared to B6 mice (Pop et al. 2005). In addition, more 
recently BK. Nti et al. using FACS analysis and real-time qRT-PCR, claimed a 
profound drop of PLN CD4+Foxp3+ Tregs and Foxp3 transcripts to 0% in 5 week-
old NOD mice in comparison to autoimmune-free B10 mice (Nti et al. 2012).  
Although there was a nonsignificant difference in the PLN Treg numbers among 
the strains, there was a displayed non-significant trend towards decrease in the 
absolute number of Tregs of NOD-RAG-GFP and B-KO mice compared to the 
control at the pre-diabetic stage (Fig.1.14 and 1.18) that agrees with the notion of 
SM. Pop et al. and BK. Nti et al. of a decrease in PLN Tregs of NOD mice. 
However, we rationalised those findings due to a nonsignificant decrease in total 
PLN numbers (i.e. cellularity) and not due to genuine PLN Treg decline in pre-
diabetic NOD mice as there were no alterations in their frequencies (Fig.1.14 and 
1.18). Additionally, the small number of mice used could overshadow the genuine 
pattern either towards an increase or decrease of PLN Tregs in NOD mice at the 
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pre-diabetic stage, therefore repetition of these experiments with more mice is 
vital in order to either verify or dispute the patterns we observed. On the other 
hand, similarly to our findings there were no alterations of PLN Tregs in NOD 
mice in an age-dependent manner as depicted by RJ. Mellanby et al. (Mellanby 
et al. 2007). Therefore, based on our current results we support the notion of no 
compromise in Treg proportions in an age-dependent manner of NOD mice. 
Although we did not investigate whether the function of these Tregs was impaired 
as they age-declined, it is possible as demonstrated previously in other peripheral 
Tregs, a defective function in suppressing the proliferation of effector T cells (You 
et al. 2005, Mellanby et al. 2007). In regards to B cell deficient NOD mice, the 
patterns observed in PLN Treg numbers were similar to NOD mice despite age 
with only one distinct decrease in both their frequency and number of old B-KO 
mice compared to FVB-RAG-GFP (Fig.1.14B and C). This may be accounted by 
a decrease in their proliferation based on their absolute number in comparison to 
control, but not reflected by their frequency (Fig.1.14D and E). However, there 
seems to be no effect on Treg homeostatic proliferation in the pancreatic lymph 
node environment by B cells of young mice (Fig.1.18). These results in 
combination with our previous thymic investigations, support a concept that 
during autoimmunity, distinct anatomic sites play different independent roles in 
the disease progression (Ochando et al. 2005). 
 
4.3 Conclusions and future directions 
  
Investigations on potential effects of B cells on Treg development in the thymus 
have not been investigated extensively in addition to exploring the homeostasis of 
ND and mature Tregs in the thymus in type 1 diabetic RAG-GFP mice. Hence, we 
sought to observe the development and homeostasis of Tregs in primary lymphoid 
organs and their homeostasis in secondary lymphoid organs using for the first time 
RAG-GFP mice. Based on our results, we hypothesize an early developmental 
fault in thymic Tregs of NOD mice that emphasize the argument that efficacious 
prevention of T1D will require detection of incidences occurring at earlier events in 
the process. Furthermore, documented alterations in the thymus do not seem to 
be accounted by compromised IL-2 levels implying normal survival based on IL-2. 
In regards to the periphery, we support the notion of an increase in splenic Tregs 
in NOD and B-KO mice with B cells affecting splenic Treg homeostatic proliferation 
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in an age-dependent manner. However, based on our current results, overall there 
seemed to be no alterations in PLNs among the strains despite age, signifying a 
potential functional defect in PLN Tregs rather than a decrease in their number 
rationalizing T1D progression. Therefore, in addition to repeating the above 
experiments in order to verify these future studies investigating the numbers of 
Tregs should be coupled with investigations on Treg functionality among different 
tissues as defining Treg populations at distinct anatomic compartments might 
signify the exact sites where impairments take place. In addition, future 
experiments should include investigations on the ability of thymic Tregs to egress 
the thymus and migrate to peripheral lymphoid organs by looking at S1P1 molecule 
in order to elucidate the increase in thymic NOD resident Tregs. Also, IL-2 levels 
should be investigated in other secondary lymphoid organs which might explain 
the increase in splenic Tregs. In addition, it is worth investigating if there are any 
spatial interactions between B cells and Tregs in the spleen or even the thymus 
based on colocalisation observed using tissue fluorescence analysed on confocal 
microscope. Furthermore, cell apoptosis assays of Tregs again in primary and 
secondary lymphoid organs are vital for a more defined Treg homeostasis in T1D 
mice.  
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